



57th AISF ANNUAL MEETING

Italian Association for the Study of the Liver

ROME, MARCH 27th/28th, 2025





AISF - Associazione Italiana per lo Studio del Fegato

Viale Maresciallo Pilsudski, 118 • 00197 Roma

Tel. 06 86399303 • E-mail info@webaisf.org

Web www.webaisf.org

AISF GOVERNING BOARD

Vincenza Calvaruso, *Palermo (Segretario)*

Roberta D'Ambrosio, *Milano*


Giacomo Germani, *Padova*

Stefano Gitto, *Firenze*

Vincenzo La Mura, *Milano*

Giuseppe Marrone, *Roma*





PROGRAMMA - 27 MARZO 2025

EARLY MORNING WORKSHOP (No E.C.M.)

ROOM GH

08.00 **NEW THERAPEUTIC APPROACHES
TO HCC**

Chairs: M. Iavarone, F.R. Ponziani

PININFARINA

08.00 **ACLF AND ALCOHOL**

09.00 Chairs: G. Perricone, G. Tosetti

ROOM A

08.00 **MANAGEMENT OF MASLD**

09.00 Chairs: L. Abenavoli, M. Masarone

AUDITORIUM

09.00 **WELCOME & INTRODUCTION**

09.15 AISF Governing Board


09.15 **GENERAL SESSION 1**

10.15 Chairs: E.G. Giannini, F.P. Russo

**Terminology, diagnosis and management
of primary biliary cholangitis -autoimmune
hepatitis variant syndrome (PBC-AIH):
results from an international Delphi
consensus process**

Presenter: A. Gerussi (Monza)

Abstract Authors: A. Gerussi, M. Sebode,
E. Nofit, A. Stoelinga, D. Bernasconi,
A. Leburgue, P. Invernizzi, C. Schramm,
B. Van Hoek, D. Tiniakos, L. Terracciano,
M. Carbone, A. Lohse on behalf of the ERN
RARE-LIVER, Global PBC Study Group and
International Autoimmune Hepatitis Group
Monza, Hamburg (Germany), Leiden (The
Netherlands), Paris (France), Newcastle upon



PROGRAMMA - 27 MARZO 2025

Tyne (UK), Athens (Greece), Pieve Emanuele (MI), Rozzano (MI), Milan

Metabolic and Functional Characterization of CD8+ T-Cell Subpopulations in Hepatocellular Carcinoma: Implications of Tumor Microenvironment on T-Cell Dysfunction

Presenter: A. Montali (Parma)

Abstract Authors: A. Montali, V. Reverberi, A. Pelagatti, A. Vecchi, M. Rossi, S. Doselli, B. Farina, A. Olivani, G. Economopoulos, R. Dalla Valle, P. Fisicaro, C. Boni, G. Missale
Parma

Exploring the impact of mitochondrial biomarkers on HCC risk according to etiologic drivers: a multicenter study

Presenter: M. Longo (Milan)

Abstract Authors: M. Longo, A. Cespiati, E. Paolini, M. Meroni, D. Smith, A. Alisi, L. Miele, A. Dalbeni, R. Lombardi, G. Soardo, A.L. Fracanzani, P. Dongiovanni
Milan, Rome, Verona, Udine

Coronary angiography in liver transplant work-up: report from a large multicenter Italian cohort


Presenter: M. Saracco (Turin)

Abstract Authors: M. Saracco, P. Burra, V. Giannelli, G. Marrone, M.C. Morelli, D. Pagano, F.R. Ponziani, G. Svegliati Baroni, P. Toniutto, M. Biolato, S. Cariati, F. D'Arcangelo, N. De Maria, C. Di Benedetto, F.M. Donato, S. Fagioli, A. Ferrarese, E. Fumolo, A. Galeota Lanza, I. Lenci, L. Mameli, B. Magro, S. Marengo, L. Pasulo, M. Rendina, R. Viganò, M.V. Picciaiola, S. Martini

Turin, Padua, Rome, Bologna, Palermo, Ancona, Udine, Genoa, Modena, Milan, Bergamo, Verona, Naples, Cagliari, Bari

Role of spleen stiffness measurement by vibration-controlled transient elastography at 100Hz in guiding invasive hemodynamic reassessments after underdilated TIPS

Presenter: D. Saltini (Modena)



PROGRAMMA - 27 MARZO 2025

Abstract Authors: D. Saltini, T. Guasconi,
C. Caporali, M. Bianchini, F. Casari,
F. Prampolini, B. Lei, M. Scoppettuolo,
F. Ascari, A.S. Velasco Mayorga, A. Piscopo,
A. Colecchia, F. Schepis
Modena

10.15 STATE OF THE ART LECTURE

**10.45 Recompensation in cirrhosis: patient
discharge or change of paradigm?**

Thomas Reiberger
Presenter: P. Caraceni

EXHIBITION AREA

10.45 Coffee Break

11.15

AUDITORIUM

11.15 SYMPOSIUM I

**12.15 ADVANCES IN AUTOIMMUNE
LIVER DISEASE**

Chairs: P. Invernizzi, C. Rigamonti

**First-Line Therapy in AIH:
comparing AZA and MMF**

N. Cazzagon

**Second line therapy for PBC:
evaluating efficacy in Real-world
and Clinical Trial Settings**


U. Vespasiani Gentilucci

**Drivers of Disease Progression
in Primary Sclerosing Cholangitis:
Implications for Risk Assessment**

M. Carbone

12.15 PREMIO ALLA CARRIERA
12.30 PROF. PAOLO ANGELI

Presenter: P. Burra



PROGRAMMA - 27 MARZO 2025

12.30 **POLICY, PUBLIC HEALTH AND**
13.00 **ADVOCACY NETWORK**

AISF Governing Board, Ivan Gardini

EXHIBITION AREA

13.00 **Lunch & poster view**
14.00

ROOM GH

14.00 **CPT SYMPOSIUM** (No E.C.M.)
15.00 **CHALLENGING ISSUES IN LIVER**
TRANSPLANTATION TODAY

Chairs: V. Giannelli, S. Martini, D. Pagano

Introduction of the symposium

P. Toniutto

Physical, psychosocial, economic issues

D. Dondossola

Patients over 70 years old

M.C. Morelli

Patients with use of illicit substances

M. di Nicola

Discussion

*Discussants: G. Marrone, F.R. Ponziani,
G. Svegliati Baroni*

Conclusions of the day

P. Burra


SALA DELL'ARCHITETTURA + SALA DELL'EDITORIA

14.00 **ULTRASOUND LAB** (No E.C.M. - Under 30)
15.00 *N. De Matthaeis, M. Fraquelli, G. Galati,
D. Roccarina*

ROOM GH

15.00 **PARALLEL SESSION 1** (No E.C.M.)
15.50 *Chairs: S. Fagioli, A. Federico*

**Feasibility and effectiveness of liver
transplantation following immunotherapy
in patients with hepatocellular carcinoma**



PROGRAMMA - 27 MARZO 2025

Presenter: G. Amaddeo (Créteil, France)

Abstract Authors: G. Amaddeo, M. Allaire, M.S. Franzè, C. Dupré, S. Caruso, T. Antonini, Y. Chouik, H. Regnault, A. Beaufrère, J. Ursic-Bedoya, M. Ningarhari, T. Uguen, A. Jaillais, O. Roux, L. Blaise, R. Gerolami, A. Pascale, R. Brustia, D. Sommacale, J. Dumortier, V. Leroy
Créteil (France), Paris (France), Lyon (France), Clichy (France), Montpellier (France), Lille (France), Rennes (France), Tours (France), Bobigny (France), Marseille (France), Villejuif (France)


One-year changes in alt and lsm, not in cap, predict long-term liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease

Presenter: G. Pennisi (Palermo)

Abstract Authors: G. Pennisi, G. Infantino, G. Di Maria, E. Tsochatzis, E. Bugianesi, M. Yoneda, M.H. Zheng, H. Hagström, J. Boursier, J.L. Calleja, G. Boon-Bee Goh,

W.K. Chan, R. Gallego-Durán, A.J. Sanyal, V. de Lédinghen, P.N. Newsome, J.G. Fan, L. Castéra, M. Lai, C. Fournier-Poizat, G. Lai-Hung Wong, A. Armandi, A. Nakajima, W.Y. Liu, Y. Shang, M. de Saint-Loup, E. Llop, K.K. Jun Teh, C. Lara-Romero, A. Asgharpour, S. Mahgoub, M.S.W. Chan, M. Romero-Gomez, H. Lin, S.U. Kim, T. Cheuk-Fung Yip, A. Tulone, J. Che-To Lai, B. Yang, H.W. Lee, G. Ciacimino, M. Enea, C. Cammà, V.W.S. Wong, S. Petta
Palermo, London (UK), Turin, Yokohama (Japan), Wenzhou (China), Stockholm (Sweden), Angers (France), Madrid (Spain), Singapore, Kuala Lumpur (Malaysia), Seville (Spain), Richmond (USA), Paris (France), Shanghai (China), Clichy (France), Boston (USA), Hong Kong (China), Birmingham (UK), Seoul (Korea, Rep. of South)

The early dynamic changes of radiological and biochemical scores help identify a more aggressive PSC phenotype



PROGRAMMA - 27 MARZO 2025

Presenter: E. Catanzaro (Padua)

Abstract Authors: E. Catanzaro, M. Peviani, E. Bonaiuto, F. Pezzato, M. Benatti, M. Gambato, P. Burra, R. Motta, N. Cazzagon Padua

MASLD and FIB4 are independent predictors of major adverse liver outcomes and cardiovascular events in type 2 diabetes: findings from a single-center cohort using AI-driven machine learnin

Presenter: V. Calvez (Rome)

Abstract Authors: V. Calvez, C. Dachena, L. Petrucci, A.R. Barberio, L. Antenucci, C. Masciocchi, A. Liguori, A. Sciarra, L. Tartaglione, S. Paternello, A. Gasbarrini, D. Pitocco, L. Miele Rome

PININFARINA

15.00 **PARALLEL SESSION 2** (No E.C.M.)

15.50 Chairs: E. Claar, M. Rendina

The early impact of bariatric surgery on liver fibrosis and steatosis in MASLD patients


Presenter: V. Cossiga (Rome)

Abstract Authors: V. Cossiga, M. Capasso, S. Albano, V. Schiavone, L. Ranieri, F. Capozzi, A. Franzese, M. Guarino, M. Musella, F. Morisco Naples

HDV persistence acts independently from HBV reservoir extent and is sustained by HBsAg production mainly derived from integrated HBV-DNA

Presenter: S. D'Anna (Rome)

Abstract Authors: S. D'Anna, L. Piermatteo, G. Brancaccio, E. Teti, A. Di Lorenzo, I. Grossi, G. Torre, V. Malagnino, M. Iannetta, F. Ceccherini-Silberstein, C. Pasquazzi, U. Cillo, A. Vitale, E. Gringeri, M. Magrofuoco, M. Pacenti, L. Baiocchi, S. Francioso, I. Lenci, A. Koffas, A.M. Geretti, M.L. Abate, A. Olivero, G.B. Gaeta, L. Sarmati, M. Rizzetto, U. Gill, P. Kennedy,



PROGRAMMA - 27 MARZO 2025

G.P. Caviglia, V. Svicher, R. Salpini
Rome, Padua, London (UK), Turin, Naples

Expert-Validated Framework for Large Language Models in HCV Care: A Comparative Analysis of RAG and Fine-Tuning Using Clinical Guidelines

Presenter: M. Giuffrè (New Haven, USA)

Abstract Authors: M. Giuffrè*, N. Pugliese*, S. Kresevic, M. Ajcevic, F. Negro, M. Puoti, X. Forns, J.M. Pawlotsky, D.L. Shung†, A. Aghemo**

*Junior co-authorship, **Senior co-authorship
New Haven (USA), Pieve Emanuele (MI), Rozzano (MI), Trieste, Geneva (Switzerland), Milan, Barcelona (Spain), Madrid (Spain), Créteil (France), Paris (France)

Changes in body mass composition do not predict post-transplant outcome in cirrhosis patients with hepatocellular carcinoma undergoing liver transplantation

Presenter: F. D'Arcangelo (Padua)

Abstract Authors: F. D'Arcangelo, M. Marchiori,

J. Lanari, A. Ferrarese, M. Gambato, S. Piano, G. Germani, F. P. Russo, M. Senzolo, P. Angeli, U. Cillo, P. Burra, A. Zanetto
Padua

AUDITORIUM

15.50 **GENERAL ASSEMBLY 2** (No E.C.M.)

16.05 AISF Governing Board

16.05 **SYMPOSIUM II**

17.05 **PROGRESS AND CHALLENGES IN VIRAL HEPATITIS**

Chairs: R. Bruno, A. Craxi


Challenges and opportunities in the path towards HCV elimination

A. Aghemo

Future treatment for HBV: how might we achieve functional cure

P. Lampertico

HDV Management: expert approaches to



PROGRAMMA - 27 MARZO 2025

screening and treatment

M.R. Brunetto

17.05 **GENERAL SESSION 2**

18.05 Chairs: *S. Montagnese, F. Schepis*

Trends in complications and mortality among individuals with chronic liver disease and cirrhosis: a population-based cohort study

Presenter: *F.P. Russo (Padua)*

Abstract Authors: *F.P. Russo, A. Zanetto, L. Salmaso, C. Barbiellini Amidei, S. Battistella, S. Piano, P. Angeli, P. Burra, M. Saia, U. Fedeli
Padua*

Influence of the MBOAT7 rs641738 polymorphism on the prognosis of patients with metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma

Presenter: *M. Guariglia (Turin)*

Abstract Authors: *M. Guariglia, G.P. Caviglia,*

*C. Rosso, S. Gaia, E. Rolle, M.L. Abate, A. Armandi, P. Carucci, E. Bugianesi
Turin, Mainz (Germany)*

Effect of Protease-Activated Receptor 2 inhibition by 1-Piperidinepropionic acid in lipid accumulation, inflammation and hepatocellular carcinoma development


Presenter: *P. Guerra (Padua)*

Abstract Authors: *P. Guerra, G. Villano, C.M. Rejano-Gordillo, M. Ruvoletto, A. Biasiolo, S. Quarta, P. Peña-SanFelix, S. De Siervi, S. Cagnin, C. Turato, M.L. Martínez-Chantar, P. Pontisso, A. Martini
Padua, Bizkaia (Spain), Pavia*

Genome-wide association study of noninvasive scores of fibrotic MASLD in an Italian population

Presenter: *F. Malvestiti (Milan)*

Abstract Authors: *F. Malvestiti, V. Moretti, S. Mira, O. Jamalaladi, S. Pelusi, G. Periti, L. Ronzon, L. Miano, M. Tranchina, C. Rosso, G. Pennisi, A. Armandi, A. Liguori,*



PROGRAMMA - 27 MARZO 2025

*F. Terracciani, R. Perbellini, G. Soardo,
A. Federico, U. Vespasiani Gentilucci,
L. Miele, E. Bugianesi, R. D'Ambrosio,
S. Petta, D. Prati, S. Romeo, L. Valenti*
Milan, Gothenburg (Sweden), Turin, Palermo,
Udine, Naples, Rome

**Impact of sexual dimorphism on
liver damage in patients with
metabolic-dysfunction associated
steatotic liver disease**

Presenter: E. Dileo (Turin)

Abstract Authors: E. Dileo, C. Rosso,
M. Parasiliti-Caprino, G.P. Caviglia,
F. Ponzetto, L. Leoni, G. Pennisi, A. Armandi,
M. Guariglia, F. Saba, M. Maccario, S. Petta,
G. Mengozzi, E. Bugianesi
Turin, Palermo

18.10 **UP TO DATE LECTURES**
19.10 **ON SPECIFIC TOPICS/SYMPOSIUM**

ROOM GH


18.10 **UP TO DATE LECTURE**
18.40 **ON SPECIFIC TOPICS / SYMPOSIUM**

18.40 **UP TO DATE LECTURE**
19.10 **ON SPECIFIC TOPICS/SYMPOSIUM**

PININFARINA

18.10 **UP TO DATE LECTURE**
19.10 **ON SPECIFIC TOPICS / SYMPOSIUM**

19.10 **UP TO DATE LECTURE**
19.40 **ON SPECIFIC TOPICS / SYMPOSIUM**



PROGRAMMA - 28 MARZO 2025

EARLY MORNING WORKSHOP (No E.C.M.)

ROOM GH

08.00 **APPROACH TO CHOLESTATIC DISORDERS**

09.00 Chairs: L. Cristoferi, V. Ronca

PININFARINA

08.00 **MANAGEMENT OF INFECTIONS**

09.00 **IN CIRRHOSIS**

Chairs: S. Piano, G. Zaccherini

ROOM A

08.00 **MANAGEMENT OF PATIENTS**

09.00 **WITH SUCCESSFULLY TREATED
VIRAL HEPATITIS**

Chairs: G. Brancaccio, E. Degasperi

AUDITORIUM


09.00 **GENERAL SESSION 3**

10.00 Chairs: A. Gasbarrini, M. Persico

Burden of Hepatitis D Virus infection in Italy: final results from the HDV Describe study

Presenter: G.P. Caviglia (Turin)

Abstract Authors: G.P. Caviglia, A. Loglio, M. Viganò, S. Fagiuoli, P. Colombatto, B. Coco, E. Dileo, T. Manetta, A. Olivero, G. Troshina, A. Ciancio, D. Angrisani, G.G. Di Costanzo, C.F. Magni, S. Antinori, G. Rizzardini, V. Messina, M. Milella, A. Saracino, M. Quaranta, S. Taurian, C. Quarta, G. Cariti, V. Cossiga, F. Morisco, S. Cretella, G. Verucchi, E. Biliotti, A.R. Garbuglia, G. D'Offizi, R. Cotugno, M. Barone, R. Cozzolongo, E.M. Cela, E. Falbo, G.A. Niro, M. Feasi, E. Pontali, C. Coppola, R. Rapetti, M. Pirisi, N. Capoluongo, N. Cuomo, A. Perrella, A. Izzi, T.A. Santantonio, V. Di Marco, C. Cosentino, A. Marrone, M. Pisaturo, N. Coppola, G. Cologni, M. Rizzi, F. Barbaro,



PROGRAMMA - 28 MARZO 2025

A.M. Cattelan, E. Fornasiere, P. Toniutto,
M. Pallozzi, F.R. Ponziani, M. Dallio,
M. Romeo, A. Federico, R. Viganò, L.S. Belli,
L. Rapisarda, E. Siciliano, E. Bracciamà,
A. Risicato, G. Bertino, M. Puoti, A. Civolani,
M. Distefano, E. Teti, M. Andreoni, P. Anolli,
P. Lampertico, G. Mengozzi, T. Stroffolini,
M.R. Brunetto, M. Rizzetto
Turin, Bergamo, Milan, Pisa, Naples, Caserta,
Bari, Bologna, Bologna, Rome, San Giovanni
Rotondo (FG), Castellana Grotte (BA),
Foggia, Lamezia Terme (CZ), Genoa,
Gragnano (NA), Novara, Palermo, Padua,
Udine, Milan, Catania, Cagliari, Siracusa

Duodenal organoids from patients with MASLD-cirrhosis display impaired mitochondrial energy metabolism and antioxidant defense

Presenter: F. Salomone (Catania)

Abstract Authors: F. Salomone*,

A. Filippello*, S. Di Mauro, A. Scamporrino,
A. Fichera, M. Licata, A.M. Amorini, S. Piro

*Equal contribution

Catania, Enna, Catania

High burden of MASLD and metALD in People with HIV: a call for liver fibrosis screening prioritization

Presenter: F. Cinque (Montreal, Canada - Milan)


Abstract Authors: F. Cinque, J. Milic,
R. Righetti, D. Kablawi, L. R. Ballesteros,
W. Elgretli, M. Shengir, B. Lebouché,
N. Kronfli, M.B. Klein, J. Bischoff,
A.L. Fracanzani, A. Bandera, R. Lombardi,
J.K. Rockstroh, G. Guaraldi, G. Sebastiani
Montreal (Canada), Milan, Modena, Bonn
(Germany)

Involvement of the ERG1 potassium channel in cholangiocarcinoma cell biology

Presenter: G. Alla Viligiardi (Florence)

Abstract Authors: G. Alla Viligiardi, J. Iorio,
M. Pastore, C. Duranti, R. Colasurdo,
C. Capitani, T. Lottini, A. Arcangeli, C. Raggi,
F. Marra
Florence

Real-world practice patterns on the use of terlipressin in patients with cirrhosis and




PROGRAMMA - 28 MARZO 2025

acute kidney injury - results from the ICA- GLOBAL AKI study

Presenter: S. Incicco (Padua)

Abstract Authors: S. Incicco, A. T. Ma, A. Juanola, K. Patidar, A. Barone, A. Kulkarni, J. L. Perez-Hernandez, B. Wentworth, S. Asrani, C. Alessandria, N. Abdelaaty Abdelkader, Y. J. Wong, Q. Xie, N.T. Pyrsopoulos, S.E. Kim, Y. Fouad, A. Torre, E. Cerda Reyes, J. Diaz-Ferrer, R. Maiwall, D. Simonetto, M. Papp, E. Orman, G. Perricone, C. Sole, C. M. Lange, A. Farias, G. Pereira, A. Gadano, P. Caraceni, T. Thevenot, N. Verma, J.H. Kim, J.D. Vorobioff, J. Cordova-Gallardo, V. Ivashkin, J. P. Roblero, R. Maan, C. Toledo, O. Riggio, E. Fassio, M. Marino, P. Nabilou, V. Vargas, M. Merli, L. Lofego Goncalves, L. Rabinowich, A. Krag, L. Balcar, P. Montes, A. Z. Mattos, T. Bruns, A. M. Nur, W. Laleman, E. Carrera Estupinan, M.C. Cabrera, M. Giralda, H. Samant, S. Raevens, J. Madaleno, W.R. Kim,

J.P. Arab, J. Presa, C. Noronha Ferreira, A. Galante, O. Roux, A. S. Allegretti, R.B. Takkenberg, S. Marciano, S.K. Sarin, P. Gines, P. Angeli, E. Sola, S. Piano Padua, Toronto (Canada), Barcelona (Spain), Houston (USA), Hyderabad (India), Ciudad de Mexico (Mexico), Charlottesville (USA), Dallas (USA), Turin, Cairo (Egypt), Singapore, Shanghai (China), Newark (USA), Anyang (Korea, Rep. of South), Minia (Egypt), Lima (Peru), New Delhi (India), Rochester (USA), Debrecen (Hungary), Indianapolis (USA), Milan, Barcelona (Spain), Munich (Germany), Sao Paulo (Brazil), Rio de Janeiro (Brazil), Buenos Aires (Argentina), Bologna, Besancon (France), Chandigarh (India), Seoul (Korea, Rep. of South), Rosario (Argentina), Tlalpan (Mexico), Moscow (Russian Federation), Santiago (Chile), Rotterdam (The Netherlands), Valdivia (Chile), Rome, Hvidovre (Denmark), Vitoria (Brazil), Tel Aviv (Israel), Tel Aviv (Israel), Odense (Denmark), Vienna (Austria), Bellavista (Peru), Porto



PROGRAMMA - 28 MARZO 2025

Alegre (Brazil), Aachen (Germany), Addis Ababa (Ethiopia), Leuven (Belgium), Quito (Ecuador), Asuncion (Paraguay), New Orleans (USA), Ghent (Belgium), Coimbra (Portugal), Stanford (USA), Vila Real (Portugal), Lisboa (Portugal), Lugano (Switzerland), Clichy (France), Boston (USA), Amsterdam (The Netherlands)

10.00 **STATE OF THE ART LECTURE**
10.30 **TRANSITION FROM PEDIATRIC
TO ADULT CARE IN LIVER DISEASES:
CHALLENGES AND EXPECTATIONS**

L. D'Antiga

Presenter: *A. Grieco*

10.30 **BEST PAPER BASIC** (No E.C.M.)

10.40 *T. Pollicino, L. Valenti*

BEST PAPER CLINICAL

G. Svegliati Baroni, A. Vitale

EXHIBITION AREA

10.40 **Coffee Break**

11.10

ROOM GH

11.10 **PARALLEL SESSION 3** (No E.C.M.)

12.10 Chairs: *V. Di Marco, M. Senzolo*


Non-invasive follow-up of cardiac hemodynamics after trans-jugular intrahepatic portosystemic shunt: focus on left ventricular global longitudinal strain

Presenter: *R. Stupia* (Desenzano del Garda, BS)

Abstract Authors: *R. Stupia, M. Bevilacqua, S. Romano, F. Cattazzo, L. De Marco, D. Sacerdoti*

Desenzano del Garda (BS), Verona, Belluno

Thrombus generation under flow conditions in patients with cirrhosis and thrombocytopenia: the CirTAS-study



PROGRAMMA - 28 MARZO 2025

Presenter: N. Bitto (Milan)

Abstract Authors: N. Bitto, G. Tosetti, A. Tripodi, A. Lecchi, S. La Marca, L. Padovan, E. Scalabrino, M. Clerici, C. Caputo, A.L. Fracanzani, M. Primignani, P. Lampertico, F. Peyvandi, V. La Mura
Milan

Prognostic role of endoscopic ultrasound guided direct portal pressure gradient measurement in porto-sinusoidal vascular disorder

Presenter: L. Giuli (Rome)

Abstract Authors: L. Giuli, G. Rizzatti, M. Pallozzi, F.R. Ponziani, B. E. Annicchiarico, G. Tripodi, A. Contegiacomo, A. Posa, R. Iezzi, R. Talerico, A. Gasbarrini, A. Larghi, F. Santopaolo
Rome

Unravelling MASLD heterogeneity at single cell level in the switching towards progressive disease


Presenter: M. Meroni (Milan)

Abstract Authors: M. Meroni, E. Paolini, M. Longo, M. Battistin, E. Mosca, P. Pelucchi, A. Chiodi, A. Sula, S. Gatti, P. Dongiovanni
Milan

Systemic oxidative stress correlates with sarcopenia and pruritus severity: two independent relationships simultaneously burdening the quality of life in patients with Primary Biliary Cholangitis

Presenter: M. Dallio (Naples)

Abstract Authors: M. Dallio, M. Romeo, F. Di Nardo, C. Napolitano, P. Vaia, A. Coppola, L. Ventriglia, A. Silvestrin, C. Basile, A. Federico
Naples



PROGRAMMA - 28 MARZO 2025

PININFARINA

11.10 **PARALLEL SESSION 4** (No E.C.M.)

12.10 Chairs: *F. Morisco, M. Viganò*

Bulevirtide for patients with chronic Hepatitis D (CHD) in Italy: a multicenter prospective nationwide real-life study (D-Shield)

Presenter: *M.P. Anolli* (Milan)

Abstract Authors: *M.P. Anolli, E. Degasperì, G. D'Offizi, A. Rianda, A. Loglio, M. Viganò, A. Ciancio, Y. Troshina, M.R. Brunetto, B. Coco, S. Zaltron, L. Turco, L. Sarmati, M. Milella, P. Toniutto, L. Marinaro, F.P. Russo, A. Gori, I. Maida, A. Federico, T.A. Santantonio, E.G. Giannini, G. Verucchi, F. Morisco, A. Mangia, S. De Nicola, B. Pinchera, M. Maracci, A. Romano, S.L. Crocè, P. Gatti†, R. Zampino, M. Persico, P. Pozzoni, A. Pan, A. Pellicelli, N. Coppola, F. Pileri, M. Tonnini, A. Soria, M. Puoti, P. Lampertico*

Milan, Rome, Bergamo, Turin, Pisa, Brescia, Bologna, Bari, Udine, Padua, Sassari, Naples, Foggia, Genoa, San Giovanni Rotondo (FG), Rozzano (MI), Ancona, Trieste, Brindisi, Baronissi (SA), Lecco, Cremona, Modena, Monza

Oncostatin M modulates the biology of cholangiocarcinoma cells and the tumor microenvironment


Presenter: *N. Porro* (Florence)

Abstract Authors: *N. Porro, J. Nurcis, S. De Siervi, M. Cadamuro, C. Turato, S. Mantovani, B. Oliviero, L. Fabris, M. Mondelli, F. Marra, M. Parola, A. Caligiuri, M. Pastore, S. Cannito, A. Gentilini*
Florence, Turin, Padua, Pavia

Investigating Notch3 expression in hepatocellular carcinoma and its interplay with KDM2A

Presenter: *I. De Giorgi* (Florence)

Abstract Authors: *I. De Giorgi, T. Caruso, M.C. Scavuzzo, S. Piaggi, F. Scolari,*



PROGRAMMA - 28 MARZO 2025

*P. Faviana, S. Pillozzi, R. Del Frate, G. Paties
Montagner, F. Bartoli, A. Corti, G. Cavallini,
V. Carloni, L. Gragnani
Florence, Pisa*

Characterization of the intrahepatic immune microenvironment in a large cohort of patients with untreated hepatitis B virus infection

Presenter: M.S. Franzè (Créteil, France)

Abstract Authors: M.S. Franzè, P. Maille,
S. Caruso, J. Calderaro, Y. Bouda, A. Sessa,
S. Chevaliez, P. Ingiliz, T. Pollicino,
G. Raimondo, J.M. Pawlowsky, V. Leroy,
G. Amaddeo
Créteil (France), Messina

Fibrates in Primary Sclerosing Cholangitis: a multicenter retrospective observational study

Presenter: A. Curto (Monza - Florence)

Abstract Authors: L. Cristofori, A. Curto,
M. Maxwell, L.K. Lund, E. Nofit,
D. Bernasconi, D. D'Amato, O. Falco,

*M. Scaravaglio, F. Malinverno, A. Gerussi,
P. Invernizzi, E. Culver, C. Schramm,
D. Assis, M. Carbone
Monza, Florence, Connecticut (USA),
Hamburg (Germany), Oxford (UK), Milan*

AUDITORIUM


12.10 **SYMPOSIUM III** 13.10 **LIVER ONCOLOGY**

Chairs: S. Bhoori, F. Piscaglia

**Advancements in HCC Systemic Therapies:
evaluating safety and effectiveness**
G. Cabibbo

**New paradigms in the treatment
of unresectable colorectal liver metastasis**
U. Cillo

**Evolving concepts and therapeutic
approaches for iCCA and pCCA**
M. Marzioni



PROGRAMMA - 28 MARZO 2025

SALA DELL'ARCHITETTURA + SALA DELL'EDITORIA

- 13.10 **ULTRASOUND LAB** (No E.C.M. - Under 30)
14.10 N. De Matthaeis, M. Fraquelli, G. Galati,
D. Roccarina

EXHIBITION AREA

- 13.10 **Lunch & poster view**
14.10

AUDITORIUM

- 14.10 **GENERAL ASSEMBLY 3** (No E.C.M.)
14.55 AISF Governing Board

- 14.55 **SYMPOSIUM IV**
15.55 **MASLD & MetADL**
Chairs: F. Fracanzani, F. Marra

Interplay between metabolic dysfunction and alcohol on the progression of liver disease
S. Petta

Setting up an appropriate referral for high risk patients

E. Bugianesi

Will emerging therapies for MASLD change the natural history of the disease?

L. Miele

- 15.55 **GENERAL ASSEMBLY 4** (No E.C.M.)
16.10 AISF Governing Board

- 16.10 **2 PREMI BEST ORAL** (No E.C.M.)
16.15 **2 PREMI BEST POSTERS** (No E.C.M.)


Clinical

V. Giannelli, R. Sacco

Basic

C. Saitta, F. Salomone

- 16.15 **CLOSING REMARKS**
16.30 AISF Governing Board



1. When glecaprevir/pibrentasvir ultra-short therapy is enough to eradicate HCV infection

A. Grassi, N. Celli, S. Maccariello, G. Donati,
A. Fabbri, G. Ballardini
Rimini, Cattolica (RN)

2. Early hepatic decompensation is the main driver of mortality in patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab or Sorafenib

G. Cabibbo, C. Celsa, S. Battaglia, M. Enea,
G. Di Maria, A. Grova, R. Ciccio, G.F. Manfredi,
M. Iavarone, A. Vogel, A.G. Singal, M. Reig,
D.J. Pinato, C. Cammà
Palermo, London (UK), Novara, Milan, Hannover
(Germany), Toronto (Canada), Dallas (USA),
Barcelona (Spain), Madrid (Spain)

3. The spleen area affects the performance of the platelet count-based non-invasive tools in predicting hepatic decompensation in MASLD-related advanced chronic liver disease


M. Dallio, M. Romeo, F. Di Nardo, C. Napolitano,

P. Vaia, C. Basile, A. Coppola, L.M. Vitale,
M. Niosi, A. Federico
Naples

4. The prognostic impact of comorbidities in patients with hepatocellular carcinoma: a multicenter observational study

F. Pelizzaro, E. Pinto, F.P. Russo, M. Gambato,
S. Famularo, F. Piscaglia, G. Cabibbo, F. Trevisani,
G. Ghittoni, A. Sangiovanni, G. Missale, F. Marra,
F.G. Foschi, C. Saitta, G. Svegliati Baroni,
. Morisco, E.G. Giannini, S. Boninsegna,
M. Di Marco, G. Vidili, F.R. Ponziani, A. Martini,
R. Sacco, M.R. Brunetto, A. Mega, F. Azzaroli,
D. Magalotti, G. Nardone, D. Sacerdoti, F. Farinati
on behalf of the ITA.LI.CA study group
Padua, Pieve Emanuele (MI), Rozzano (MI),
Bologna, Palermo, Viterbo, Milan, Parma,
Florence, Faenza (RA), Messina, Ancona, Naples,
Genoa, Negrar (VR), Seriate (BG), Sassari, Rome,
Foggia, Pisa, Bolzano, Verona

5. Workforce reintegration for liver transplant



recipients: interdisciplinary assessment of unemployment risk factors

M. Saracco, A. Godono, M. Maci, A.C. Surra, G. Curoso, F. Angelino, C. Arnone, S. Strona, B. Papaleo, S. Sottile, M.V. Picciaiola, P. Boffetta, C. Frasccheri, E. Pira, A. Ottobrelli, D. Cocchis, G.M. Saracco, R. Romagnoli, S. Martini
Turin, Bologna

6. Hepatitis delta virus (hdv) replication through hbv integrants in hcc recurrence after liver transplantation

L. Di Marco, N. De Maria, A. Pivetti, A. Colecchia, A. Romanzi, A. Spallanzani, G. Guaraldi, G. Dolci, G. Ciusa, F. Di Benedetto, P. Magistri, S. Di Sandro, E. Degasperis, M.P. Anolli, P. Lampertico, D. Giosa, D. Lombardo, G. Raimondo, T. Pollicino
Modena, Palermo, Milan, Messina

7. Outcomes and safety of DAA treatment in HCV cirrhotic patients treated with Atezolizumab- Bevacizumab for hepatocellular

carcinoma


L. Stella, G. Cabibbo, M. Iavarone, F. Piscaglia, F. Tovoli, F. Marra, C. Mazzarelli, R. Tortora, A. Aghemo, S. De Nicola, S. Bhoori, M. Pallozzi, A. Gasbarrini, L. Cerrito, F.R. Ponziani
Rome, Palermo, Milan, Bologna, Florence, Naples

8. AI-Driven Diagnosis: Enhancing HCV-Related Cirrhosis Detection with Multilayer Perceptron Networks

F. Bronte, A. Affronti, F. Gambino, G. Mogavero, M.G. Bavetta, M.R. Barcellona, G. Fusco, S. Esposito, A.V. Gaddi, E. Aragona
Palermo, Parma, Bologna

9. Evidence of durable response to bepirovirsen in B-Clear On-NA responders: B-Sure second report

S.G. Lim, T. Asselah, G.I. Diaconescu, A. Gadano, N.U. Gankina, S. Marciano, G. Rizzardini, T. Stepanova, H.J. Yim, M.F. Yuen, A. Walker, C. Macfarlane, S. Corson, J. Dong, H. Plein, A. Delli Carri, G. Quinn, S. Kendrick, M. Paff,



D. Theodore, R. Elston

Singapore, Clichy (France), Craiova (Romania), Buenos Aires (Argentina), Krasnojarsk (Russian Federation), Milan, Moscow (Russian Federation), Ansan (Republic of Korea), Hong Kong (China), Brentford (UK), Waltham (USA), Glasgow (UK), Shanghai (China), Verona, Hertfordshire (UK), Collegeville (USA), Durham (USA)

10. Analysis of HBV genotype association to bepirovirsen treatment response in patients with chronic HBV infection (Phase 2b B-Clear study)

J. Bouquet, R. Elston, P. Yates, S. You, A.S Youssef, A. Nader, J. Cremer, T. Milano, G. Quinn, F. Campbell, M. Paff, D. Theodore
San Francisco (USA), Hertfordshire (UK), Collegeville (USA), Durham (USA), Verona

11. Bepirovirsen immune mechanism of action may potentiate infected hepatocyte killing: Indirect evidence from B-together peripheral longitudinal biomarker analysis

S. Joshi, J. Freudenberg, J. Singh, L. Felton, S. Dixon, V. Maestrini, M. Paff, D. Theodore, J. Walker


Collegeville (USA), London (UK), Verona, Research Triangle Park (USA), San Francisco (USA)

12. Investigation of linerixibat 40 mg BID for cholestatic pruritus of primary biliary cholangitis (PBC); further data from the Phase 2b GLIMMER study to support the Phase 3 GLISTEN study

J. Fettiplace, B. Swift, S. Zhang, P. Invernizzi, R. von Maltzahn, M. M. McLaughlin
London (UK), Research Triangle Park (USA), Collegeville (USA), Monza

13. Mri-based clinical-radiomics analyses of colorectal liver metastases to predict tumor growth patterns by machine learning approach

S. Famularo, E.H. Tran, A. Ammirabile, L. Boldrini, C. Bonifacio, C. Mele, E. Boccia, E. Genco, G. Costa, F. Giuliani, G. Torzilli, L. Viganò, F. Ardito
Rome, Strasbourg (France), Pieve Emanuele (MI),



Milan, Bergamo

14. Efficacy and safety of atezolizumab/bevacizumab for hepatocellular carcinoma in a real-life prospective cohort: A 2024 update

B. Stefanini, M. Iavarone, F. Marra, G. Cabibbo, C. Vivaldi, A. Palloni, C. Soldà, F.R. Ponziani, G. Tesini, F. Piscaglia, E. Alimenti, C. Campani, C. Celsa, G. Masi, G. Brandi, S. Lonardi, L. Stella, T. Pressiani, L. Lani, A. Dalbeni, G. Svegliati Baroni, P. Federico, F.G. Foschi, S. De Lorenzo, F. Tovoli on behalf of the ARTE study group
Bologna, Milan, Florence, Palermo, Pisa, Padua, Rome, Rozzano (MI), Verona, Ancona, Naples, Faenza (RA)

15. Management of ascites in elderly patients with cirrhosis: results of an Italian survey

S. Di Cola, L. Lapenna, M. Spigaroli, M. Merli
Rome

16. Prevalence of HBV and HCV infections

among at-risk migrant and refugee populations in Italy: 2-year results of the VH-COMSAVAC European project

G. Colucci, E. Sguazzini, R. Damonte, G. Romanò, A. Spada, R. Cassola, P. Lampertico
Milan

17. MPEP combines mGluR5 inhibition and AMPK activation to reduce hepatic steatosis


M. Trucchi, L.G. Di Pasqua, F. Protopapa, S. Lotti, A.C. Croce, M. Vairetti, F. Nicoletti, A. Ferrigno
Pavia, Rome, Pozzilli (IS), Pisa

18. Enterobius vermicularis infection mimicking liver malignancy

C. Simoni, J. Testa, L. Maroni, B. Castiglioni
Busto Arsizio (VA), Gallarate (VA)

19. Predictors of esophago-gastric varices and variceal bleeding in patients receiving atezolizumab/bevacizumab for unresectable hepatocellular carcinoma

S. Ascari, R. Chen, M. Iavarone, B. Stefanini,



F. Marra, G. Cabibbo, C. Vivaldi, A. Palloni, C. Soldà, F.R. Ponziani, E. Valenzi, F. Ravaioli, E. Franceschini, G. Tosetti, C. Campani, C. Celsa, G. Masi, G. Brandi, S. Lonardi, L. Stella, T. Pressiani, L. Lani, A. Dalbeni, G. Svegliati Baroni, P. Federico, L. Ielasi, S. De Lorenzo, F. Piscaglia, F. Tovoli
Bologna, Milan, Florence, Palermo, Pisa, Bologna, Padua, Rome, Rozzano (MI), Verona, Ancona, Naples, Faenza (RA)

20. Long-term outcomes after Combined Liver-Kidney Transplantation: a single center experience

F. Leonardi, L. Pasulo, M. Viganò, F. Neri, A. Amaduzzi, A.R. Plati, P.L. Ruggerenti, D. Pinelli, S. Fagioli
Bergamo, Milan

21. To re-transplant, or not to re-transplant, that is the question

F. Leonardi, L. Pasulo, M. Triolo, M.G. Luca', C. Iegri, A. Loglio, M. Viganò, S. Camagni, M.


Guizzetti, I. Riva, T.M. Valetti, D. Pinelli, S. Fagioli
Bergamo, Milan

22. AI-AD score: a novel Machine Learning-based model for predicting Acute Liver Decompensation progression a prospective observational study

A. Dalbeni, M. Vicardi, M. Bicego, A. Mantovani, F. Cattazzo, M. Bevilacqua, M. Zoncapè, L. De Marco, K. Donadello, L. Alaimo, A. Ruzzenente, V. Paon, D. Ieluzzi, D. Sacerdoti
Verona

23. Statins in patients with advanced hcc treated with atezolizumab/bevacizumab: a propensity score-matched cohort analysis from arte an Italian prospective multicentric dataset

A. Dalbeni, F. Cattazzo, A. Auriemma, F. Tovoli, M. Iavarone, F. Marra, G. Cabibbo, C. Vivaldi, A. Palloni, C. Soldà, M. Vicardi, L.A. Natola, E. Franceschini, M. Bruccoleri, C. Campani, C. Celsa, G. Masi, G. Brandi, S. Lonardi, F.R. Ponziani, L. Rimassa, T. Pressiani, L. Stella,



L. Lani, G. Svegliati Baroni, P. Federico, F. Foschi, S. De Lorenzo, D. Sacerdoti
Verona, Bologna, Milan, Florence, Palermo, Pisa, Padua, Rome, Rozzano (MI), Ancona, Naples, Faenza (RA)

24. RuvBL1/2 ATPase activity is required for HSF1-mediated stress response in hepatocellular carcinoma

D. Papini, A. Guida, I. Simeone, F. Vannucci, G. Defazio, S. Polvani, E. Ceni, A. Ficarelli, G. Dragoni, T. Innocenti, L. Picariello, A. Galli, T. Mello
Florence, Siena

25. Features and factors related to intensive care unit admission of cirrhotic patients with Acute-on-Chronic Liver Failure: a single-center observational study

L. De Marco, A. Dalbeni, M. Bevilacqua, R. Stupia, F. Cattazzo, K. Donadello, D. Sacerdoti
Belluno, Verona, Desenzano del Garda (BS)

26. The real life use of bulevirtide for treatment of chronic HDV infection: an interim analysis in the PITER cohort


PITER Collaborating Investigators

27. Antinuclear antibodies target unknown autoantigens in porto-sinusoidal vascular disorder (PSVD) without portal hypertension

N. Pugliese, A. Tonutti, N. Isailovic, D. Polverini, A. Ceribelli, S. De Nicola, M. De Santis, C. Selmi, A. Aghemo
Milan, Rozzano (MI)

28. Assessing the diagnostic accuracy of ChatGPT-4 in the histopathological evaluation of liver fibrosis in metabolic dysfunction-associated steatotic liver disease

T. Laohawetwanit, D. Panzeri, R. Akpinar, N. Pugliese, C. De Carlo, V. Belsito, L. Terracciano, A. Aghemo, G. Chirico, D. Inverso, J. Calderaro, L. Sironi, L. Di Tommaso
Milan, Pathum Thani (Thailand), Créteil (France)



29. Fibrate-Oca (FI-OCA) Study a Global snapshot of PBC practice around the Glob

V. Ronca, A. De Vincentis, F. Terracciani, U. Vespasiani Gentilucci, L. Cristoferi, A. Gerussi, M. Scaravaglio, C. Corpechot, A. Tanaka, G. Cancado, N. Abbas, K. Olsen, S. Rodriguez-Tajes, M.C. Londono, N. Gatselis, V. Lygoura, G. Dalekos, E. Lytyyak, A. Montano-Loza, E. Culver, F. Nevens, E. Eikelenboom, A. Van der Meer, E. Zigmond, V. Calvaruso, L. Sierra, R. Barba Bernal, A. Bonder, A. Villamil, X. Verhelst, C. Levy, G. Hirschfield, A. Lleo, P. Trivedi, P. Invernizzi, B. Hansen, M. Carbone
Pieve Emanuele (MI), Rozzano (MI), Rome, Milan, Paris (France), Tokyo (Japan), Toronto (Canada), Birmingham (UK), Larissa (Greece), Thessaly (Greece), Edmonton (Canada), Oxford (UK), Leuven (Belgium), Rotterdam (The Netherlands), Tel Aviv (Israel), Palermo, Boston (USA), Buenos Aires (Argentina), Ghent (Belgium), Miami (USA)

30. Somatic copy number alterations in circulating cell-free DNA as a predictive

biomarker for hepatocellular carcinoma: insights from a proof-of-concept study


E. Pinto, E. Lazzarini, F. Pelizzaro, M. Gambato, L. Santarelli, S. Potente, P. Zanaga, T. Zappitelli, R. Cradin, P. Burra, F. Farinati, C. Romualdi, V. Tosello, S. Indraccolo, F.P. Russo
Padua

31. Prognostic value of a composite biomarker score for predicting overall survival in HCC patients

F. Damone, G.P. Caviglia, P. Colombatto, F. Oliveri, G. Ricco, M. Guariglia, S. Gaia, V. Romagnoli, D. Cavallone, E. Rolle, P. Carucci, F. Bonino, M.R. Brunetto
Pisa, Turin, Rome

32. Creatinine as a predictor of clinical events in Metabolic Dysfunction-Associated Steatotic Liver Disease

G. Di Betto, A. Farina, P. Palumbo, B. Patrizi, R. Righetti, S. Ferrarini, E. Corradini, A. Pietrangelo, E. Buzzetti



Modena

33. The changing epidemiology of patients with HCC receiving a first-line systemic therapy: insights from ARPES and ARTE databases (2008-2024)

L. Lani, F. Piscaglia, G. Zaccherini, A. De Sinno, B. Stefanini, M. Iavarone, F. Marra, G. Cabibbo, C. Vivaldi, A. Palloni, C. Soldà, L. Stella, M. Bruccoleri, C. Campani, C. Celsa, G. Masi, G. Brandi, S. Lonardi, F.R. Ponziani, L. Rimassa, T. Pressiani, A. Dalbeni, G. Svegliati Baroni, P. Federico, L. Ielasi, S. De Lorenzo, P. Caraceni, F. Tovoli
Bologna, Milan, Florence, Palermo, Pisa, Bologna, Padua, Rome, Verona, Ancona, Naples, Faenza (RA)

34. Multiparametric ultrasound-based algorithm SteatoScore2.0 versus monoparametric Controlled Attenuation Parameter in clinical practice: a comparison study in a monocentric MASLD cohort

G. Petralli, A. Salvati, S. Cappelli, L. Surace, G. Ricco, P. Colombatto, L. De Rosa, F. Faita, M.R. Brunetto
Pisa


35. Activation of AMPK by a novel complex I modulator (CIM) reduces lipid accumulation and mitigates fibrosis in an in vivo model of MASLD

F. Protopapa, A. Ferrigno, M. Trucchi, S. Lotti, M. Vairetti, A.C. Croce, P. Sun, S.G. Kauschke, L.G. Di Pasqua
Pavia, Biberach an der Riss (Germany)

36. Usefulness of cardiology specialist follow up after liver transplant

E.N. Lynch, M. Tanturli, G. Lubian, A. Curto, S. Petruccelli, T. Innocenti, G. Dragoni, S. Gitto, D. Ghinolfi, A. Galli
Florence, Siena, Pisa

37. Wilson disease: presentation, clinical course and complications in a large cohort of patients attending San Paolo Hospital of Milan



*F. Samartin, S. Vavassori, A.L. Crosignani,
E. Bertolini, P.M. Battezzati*
Milano

38. Quantitative morphometric analysis via artificial intelligence-driven image analysis in autoimmune hepatitis: a multi-center study

*G. Cazzaniga, E. Merelli, B. Engel, F. Bolis,
A. Marini, E. Nofit, L. Cristoferi, D. Bernasconi,
F. Malinverno, R. Viganò, R. Taubert, G. Chiarello,
M. Camozzi, F. Pagni, M. Carbone, P. Invernizzi,
A. Gerussi*
Milan, Monza, Hannover (Germany)

39. Characterization of a cohort of liver transplant patients for HBV and/or HBV/HDV related complications: results of a Campania multicenter study

*G. Stornaiuolo, L. Salmoni, A. Russo,
D. Angrisani, A. Santonicola, G. Valente,
F. Longobardi, F. Morisco, M. Persico,
M. Stanzione, C. Sagnelli, M. Pisaturo, N. Coppola*
Naples, Salerno, Caserta

40. AI-based estimation of cardiovascular risk in MASLD patients using non-contrast CT imaging and clinical data


*A. Cirella, P. Bruno, V. Caputo, P. Palumbo,
S.J. Santini, A. Quarta, F. Calimeri, P. Palumbo,
E. Di Cesare, C. Balsano*
L'Aquila, Rende (CS), Rome, Avezzano (AQ)

41. One-year efficacy and safety of tacrolimus in chronic autoimmune hepatitis

*A. Gerussi, A. Curto, E. Nofit, D. Bernasconi,
A. Bonfichi, D. D'Amato, O. Falco, M. Scaravaglio,
F. Malinverno, L. Cristoferi, M. Carbone,
P. Invernizzi*
Monza, Florence, Pavia, Turin, Sassari, Milan

42. The use of Controlled Attenuation Parameter for the assessment of treatment response in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease undergoing a lifestyle intervention program

*L. Vaira, A. Armandi, C. Rosso, G.P. Caviglia,
M. Marano, F. Amato, K. Gjini, M. Guariglia,*



*E. Dileo, I. Goitre, D. Ribaldone, S. Bo,
E. Bugianesi*
Turin

43. The association between non-invasive tests of liver fibrosis and early diastolic dysfunction in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease

*F. Amato, A. Armandi, A. Andreis, M. Bellettini,
F. Lorusso, K. Gjini, M. Marano, L. Vaira, C. Rosso,
G.P. Caviglia, M. Guariglia, E. Dileo, D. Castagno,
G. Alunni, G.M. De Ferrari, E. Bugianesi*
Turin

44. Incidence of clinical outcomes in patients with MASLD and long-term follow up: results from a single center cohort study

*M. Marano, A. Armandi, G.P. Caviglia, C. Rosso,
F. Amato, L. Vaira, K. Gjini, M. Guariglia, E. Dileo,
E. Bugianesi*
Turin

45. Perception and management of liver


enzymes abnormalities among IBD specialists: Insights from an IG-IBD survey

*N. Pugliese, C. Bezzio, D. Polverini, S. Festa,
F.A. Caprioli, S. Renna, E.V. Savarino, A. Variola,
M.C. Fantini, D. Pugliese, F. Macaluso,
A. Dal Buono, C. Masetti, R. Gabbiadini, L. Loy,
A. Armuzzi, A. Aghemo*
Pieve Emanuele (MI), Rozzano (MI), Rome, Milan,
Palermo, Padua, Negrar di Valpolicella (VR),
Cagliari, Rome

46. Dynopenia predicts mortality in patients with liver cirrhosis and hepatocellular carcinoma

*P. Gallo, V. Flagiello, A. De Vincentis, S. Di Cola,
F. Terracciani, A. Falcomatà, A. Picardi,
U. Vespasiani Gentilucci*
Rome

47. Automatic generation of learning material for residential students in Emergency Departments (ED): evaluation of AI-generated flashcards for supporting medical management of gastrointestinal emergencies



A. Fontana, G. Sinatti, S. Cicchinelli, A. Cirella,
S. Jr. Santini, V. Caputo, I. Letteri, P. Vittorini,
C. Balsano
L'Aquila, Teramo, Rome

48. Large Language Model Agent-Based Framework for automated Treatment Prescription in Patients with Chronic Hepatitis C Virus Infection

M. Giuffrè, S. Kresevic, M. Ajcevic, L. Crocè,
D. Shung
New Haven (USA), Trieste

49. Treatment of portal hypertension through transjugular intrahepatic portosystemic shunt (TIPS) in patients with porto-sinusoidal vascular disease (PSVD)

M. Fazio, C. Becchetti, G. Perricone, M. Solcia,
F. Morelli, A. Alfonsi, F. Barbosa, P.M.
Brambillasca, C. Andriulo, M. Vangeli,
C. Mazzearelli, R. Viganò, M. Cucco,
A.G. Rampoldi, L.S. Belli, A. Airoidi
Milan


50. Portal Vein Recanalization-Transjugular Intrahepatic Portosystemic Shunt (PVR-TIPS) in patients with anatomical portal contraindication to liver transplantation: feasibility and clinical implication

C. Becchetti, G. Perricone, E. Motto, F. Bolis,
F. Barbosa, A. Alfonsi, F. Morelli, L. Centonze,
R. De Carlis, E. Roselli, A. Vanzulli, G. Monti,
L.S. Belli, A. Airoidi, L. De Carlis, A. Lauterio,
M. Solcia
Milan, Monza

51. Strategies to enhance Natural Killer cell response in Hepatocellular Carcinoma: The role of TGF β in NK-Cells (dys)function and plasticity

V. Reverberi, A. Montali, A. Pelagatti, A. Vecchi,
M. Rossi, S. Doselli, B. Farina, A. Olivani,
G. Economopoulos, R. Dalla Valle, P. Fisicaro,
C. Boni, G. Missale
Parma

52. Oncostatin M contributes to liver steatosis in experimental conditions of Metabolic



dysfuntion Associated Steatotic Liver Disease

J. Nurchis, S. Sutti, I. Varriale, F. Protopapa, A. Provera, S. Cannito, B. Foglia, M. Maggiora, C. Bocca, E. Albano, M. Parola, E. Novo
Turin, Novara, Pavia


53. Long-term Bulevirtide monotherapy in patients with HDV-related compensated cirrhosis: effectiveness, safety and clinical outcomes from the retrospective multicenter european study (Save-D)

E. Degasperi, M.P. Anolli, M. Jachs, T. Reiberger, V. De Ledinghen, S. Metivier, G. D'Offizi, F. di Maria, C. Schramm, H. Schmidt, C. Zöllner, F. Tacke, C. Dietz-Fricke, H. Wedemeyer, M. Papatheodoridi, G. Papatheodoridis, I. Carey, K. Agarwal, F. Van Bömmel, M.R. Brunetto, M. Cardoso, G. Verucchi, A. Ciancio, F. Zoulim, S. Aleman, N. Semmo, A. Mangia, M.N. Hilleret, U. Merle, T. Santantonio, N. Coppola, A. Pellicelli, B. Roche, X. Causse, L. D'Alteroche, J. Dumortier, N. Ganne, F. Heluwaert, I. Ollivier, D. Roulot, M. Viganò, A. Loglio, A. Federico, F. Pileri,

M. Maracci, M. Tonnini, J.P. Arpurt, K. Barange, E. Billaud, S. Pol, A. Gervais, A. Minello, I. Rosa, M. Puoti, P. Lampertico
Milan, Vienna (Austria), Bordeaux (France), Toulouse (France), Rome, Essen (Germany), Berlin (Germany), Hannover (Germany), Athens (Greece), London (UK), Leipzig (Germany), Pisa, Amadora (Portugal), Bologna, Turin, Lyon (France), Stockholm (Sweden), Bern (Switzerland), San Giovanni Rotondo (FG), Grenoble (France), Heidelberg (Germany), Foggia, Naples, Villejuif (France), Tours (France), Lyon (France), Bobigny (France), Annecy (France), Caen (France), Bergamo, Naples, Modena, Ancona, Bologna, Avignon (France), Toulouse (France), Nantes (France), Paris (France), Dijon (France), Créteil (France)

54. Autoimmunity in chronic HDV infection: results from the HDV Describe study cohort

G.P. Caviglia, E. Dileo, T. Manetta, B. Donati Marell, P. Merlach, A. Loglio, M. Viganò, S. Fagioli, P. Colombatto, B. Coco, A. Olivero,



G. Troshina, A. Ciancio, D. Angrisani,
G.G. Di Costanzo, C.F. Magni, S. Antinori,
G. Rizzardini, V. Messina, M. Milella, A. Saracino,
M. Quaranta, S. Taurian, C. Quarta, G. Cariti,
V. Cossiga, F. Morisco, S. Cretella, G. Verucchi,
E. Biliotti, A.R. Garbuglia, G. D'Offizi, R. Cotugno,
M. Barone, R. Cozzolongo, E.M. Cela, E. Falbo,
G.A. Niro, M. Feasi, E. Pontali, C. Coppola,
R. Rapetti, M. Pirisi, N. Capoluongo, N. Cuomo,
A. Perrella, A. Izzi, T.A. Santantonio, V. Di Marco,
C. Cosentino, A. Marrone, M. Pisaturo,
N. Coppola, G. Cologni, M. Rizzi, F. Barbaro,
A.M. Cattelan, E. Fornasiere, P. Toniutto,
M. Pallozzi, F.R. Ponziani, M. Dallio, M. Romeo,
A. Federico, R. Viganò, L.S. Belli, L. Rapisarda,
E. Siciliano, E. Bracciamà, A. Riscato, G. Bertino,
M. Puoti, A. Civolani, M. Distefano, E. Teti,
M. Andreoni, P. Anolli, P. Lampertico, T. Stroffolini,
M.R. Brunetto, G. Mengozzi, M. Rizzetto
Turin, Bergamo, Milan, Pisa, Naples, Caserta, Bari,
Bologna, Rome, San Giovanni Rotondo (FG),
Castellana Grotte (BA), Foggia, Catanzaro,
Lamezia Terme (CZ), Genoa, Gragnano (NA),


Novara, Foggia, Palermo, Padua, Udine, Catania,
Cagliari, Siracusa

55. Differential patterns of HBV RNA and HBcrAg levels in a large european cross-sectional study of untreated patients with chronic Hepatitis Delta

E. Degasperi, C. Scholtes, B. Testoni, S. Uceda
Renteria, M.P. Anolli, C. Charre, F. Facchetti,
M.L. Plissonnier, D. Sambarino, R. Perbellini,
S. Monico, A. Callegaro, E. García-Pras, S. Lens,
M.F. Cortese, X. Forns, S. Pérez-del-Pulgar,
M. Heil, M. Levrero, F. Zoulim, P. Lampertico
Milan, Lyon (France), Paris (France), Barcelona
(Spain), Pleasanton (USA), Rome

56. Diagnostic yield of whole exome sequencing in adult-onset cholestatic liver disease

M. Scaravaglio, L. Ronzoni, L. Cristoferi, L. Miano,
E. Nofit, A. Gerussi, F. Malinverno, V. Moretti,
V. Torcianti, C. Caime, M. Cadamuro, L. D'Antiga,
P. Invernizzi, M. Carbone, L. Valenti



Milan, Monza, Bergamo

57. Prevalence and impact of Clinically Significant Portal Hypertension (CSPH) in patients with Hepatocellular Carcinoma (HCC): a multicenter cohort study on the ITA.LI.CA database

R. Chen, M. Dibetto Rimondini, E.G. Giannini, V. Santi, F. Pelizzaro, A. Sangiovanni, G. Cabibbo, F. Marra, F. G. Foschi, G. Svegliati Baroni, F.R. Ponziani, G. Missale, F. Morisco, R. Sacco, G. Ghittoni, C. Saitta, G. Vidili, F. Azzaroli, M.R. Brunetto, S. Boninsegna, D. Sacerdoti, G. Nardone, D. Magalotti, A. Mega, A. Martini, F. Tovoli, F. Piscaglia
Bologna, Genoa, Padua, Milan, Palermo, Florence, Faenza (RA), Ancona, Rome, Parma, Naples, Foggia, Viterbo, Messina, Sassari, Pisa, Negrar (VR), Verona, Bolzano


58. Ultrasound muscular thickness-based model to identify sarcopenia in patients with portal hypertension (PH): a cross-sectional

single-center observational study

M. Lucà, G. Tosetti, V. Cardone, L. Argiento, S. Ridolfo, E. Acquati, F. Cicchetti, E. Xhepa, M. Pavan, P. Biondetti, A. Angileri, S. Stella, G. Carrafiello, P. Lampertico
Milan

59. Comparison of diagnostic performances of HDV RNA quantification assays used in clinical practice in Italy: data from the first national quality control multicenter study

L. Piermatteo, R. Salpini, G.P. Caviglia, A. Bertoli, M.R. Brunetto, B. Bruzzzone, A. Callegaro, C. Caudai, D. Cavallone, L. Chessa, F. Coghe, N. Coppola, N. Cuomo, S. D'Anna, M. Di Stefano, F. Facchetti, C. Farina, D. Ferraro, E. Franchin, D. Francisci, S. Galli, A.R. Garbuglia, W. Gennari, V. Ghisetti, P. Lampertico, N. Marascio, S. Menzo, V. Micheli, G. Niro, A. Olivero, P. Paba, C.I. Palermo, O. Palmieri, S. Paolucci, M. Pisatur, T. Pollicino, G. Raffa, G. Torre, O. Turriziani, S. Uzzau, M. Vatteroni, M. Zazzi, A. Craxì, F. Ceccherini-Silberstein, V. Svicher on behalf of



the Virology Italian Network Vironet C
Rome, Turin, Pisa, Genoa, Bergamo, Siena,
Cagliari, Caserta, Naples, Foggia, Milan, Palermo,
Padua, Perugia, Bologna, Modena, Turin,
Catanzaro, Ancona, San Giovanni Rotondo (FG),
Catania, Pavia, Messina, Sassari, Siena

60. Assessing portal hypertension with endoscopic ultrasound portal pressure gradient (eus-ppg): clinical correlations and procedural outcomes

F. Martini, L. Salvi, G. Scandali, C. Scorzoni, D. Balducci, M. Marzioni, L. Maroni, A. Benedetti, B. Moricoli, M.G. Danieli, D. Palmieri, A. Maolo, T. Piva, F. Marini, L.M. Daretti, E. Bendia, G. Tarantino
Ancona

61. Spatial transcriptomics maps the metabolic zonation of hepatocytes in MASLD I148M-PNPLA3 carriers

E. Paolini, M. Longo, M. Meroni, A.L. Fracanzani, P. Dongiovanni

Milan

62. Mapping the hepatic mtDNA genomic landscape in patients with MASLD: The Era of GPT-4 Artificial Intelligence


E. Paolini, M. Longo, M. Meroni, A. L. Fracanzani, P. Dongiovanni
Milan

63. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Italian women: s liver fibrosis independent from menopause?

R. Chen, A. Salamone, C. Abbati, R. Capelli, E. Santangeli, B. Stefanini, M.G. Indre, F. Ravaioli, F. Piscaglia, S. Ferri
Bologna

64. Prevalence and predictors of steatotic liver disease and significant liver fibrosis in an integrated hepatological and non-hepatological healthcare pathway model

A. Armandi, G.P. Caviglia, G. Beccuti, A. Andreis, F. Barutta, M. Bellettini, C. Rosso, A. Ferro,



G. Bonacchi, K. Gjini, F. Amato, M. Marano,
L. Vaira, M. Guariglia, E. Dileo, D. Castagno,
G.M. De Ferrari, G. Alunni, M. Rinaldi, G. Gruden,
E. Bugianesi
Turin

65. Liver transplants in untreated vs Bulevirtide-treated patients with chronic Hepatitis Delta: a cross-sectional, intrahepatic analysis

E. Degasperis, C. Dibenedetto, M. Maggioni,
D. Sambarino, F. Facchetti, M.P. Anolli,
M. Sagasta, S. Monico, P. Toniutto, C. Zöllner,
F. Tacke, N. Semmo, M.F. Donato, P. Lampertico
Milan, Udine, Berlin (Germany), Bern (Switzerland)

66. Similar Rates of Biochemical Response Are Observed Across Virologic Response Categories Over 96 Weeks of Bulevirtide Monotherapy in Patients With Chronic Hepatitis Delta

P. Lampertico, T. Asselah, V. Chulanov,
P. Bogomolov, T. Stepanova, M. Cornberg,
D. Manuilov, M. Li, A.H. Lau, B.L. Da, D. Tedesco,
G.M. Chee, M.R. Brunetto, S. Zeuzem, F. Zoulim,

H. Wedemeyer, S. Aleman
Milan, Clichy (France), Moscow (Russian Federation), Hannover (Germany), Foster City (USA), Pisa, Frankfurt am Main (Germany), Lyon (France), Stockholm (Sweden)


67. Anticoagulation in patients with liver cirrhosis and portal vein thrombosis

F. Cattazzo, M. Bevilacqua, L. De Marco, R. Stupia,
A. Dalbeni, A. Mantovani, D. Ieluzzi, V. Paon,
D. Sacerdoti
Verona

68. Prevalence of steatotic liver disease and steatohepatitis in a population of healthy workers

P. Guerra, J. Lopez Perez, S. Cagnin, P. Iruzubieta,
P. Pontisso, M.L. Martínez-Chantar, A. Martini
Padua, Bilbao (Spain), Santander (Spain), Derio (Spain)

69. Efficacy and safety of BLV monotherapy for chronic hepatitis delta: posttreatment results



through 48 weeks after the end of treatment from an interim analysis of a randomised Phase 3 study MYR301

S. Aleman, M. Brunetto, A. Blank, P. Andreone, P. Bogomolov, V. Chulanov, N. Mamonova, N. Geyvandova, V. Morozov, O. Sagalova, T. Stepanova, G.M. Chee, R.C. Mercier, A. Lichtman, D. Manuilov, S. Arterburn, A.H. Lau, A. Osinusi, F. Christian-Cox, F. Duff, J. Schulze zur Wiesch, M. Cornberg, S. Zeuzem, H. Wedemeyer, P. Lampertico
Stockholm (Sweden), Pisa, Heidelberg (Germany), Modena, Moscow (Russian Federation), Stavropol (Russian Federation), Samara (Russian Federation), Chelyabinsk (Russian Federation), Foster City (USA), Hamburg (Germany), Hannover (Germany), Frankfurt (Germany), Milan

70. The asymmetry of the liver and spleen stiffness measures between patients with chronic hepatitis B and D reflects clinic-pathologic differences

F. Damone, P. Colombatto, A. Pinna, G. Ricco,


D. Cavallone, G. Petralli, R. Vukotic, B. Coco, L. Surace, V. Romagnoli, F. Oliveri, F. Bonino, M.R. Brunetto
Pisa, Naples

71. Impact of liver transplantation on spleen stiffness: early findings from a single-centre study

S. Ridolfo, C. Dibenedetto, V. Cardone, M. Sagasta, E. Sguazzini, B. Antonelli, L. Caccamo, M. Fraquelli, M.F. Donato, P. Lampertico
Milan

72. Patients with cirrhosis and ascites treated with long-term albumin: An integrated management proposal based on a real-life study

E. Pompili, G. Iannone, S. Piano, P. Toniutto, A. Lombardo, S. Gioia, G. Zaccherini, M. Tonon, R. Gagliardi, M. Baldassarre, G. Tedesco, L. Lani, V. Guarneri, V. Di Marco, S. Nardelli, V. Calvaruso, D. Bitetto, P. Angeli, P. Caraceni
Bologna, Padua, Udine, Palermo, Rome



73. A dynamic contrast enhanced ultrasound based risk prediction model for the diagnosis of hepatocellular carcinoma in the grey area of ceus li-rads: The person4 model

L. Galasso, G. Esposto, P. Santini, I. Mignini, R. Borriello, M.E. Ainora, A. Gasbarrini, M.A. Zocco
Rome

74. Quantification of plasma HDV RNA in untreated and Bulevirtide-treated patients with CHD: a comparison between Robogene 2.0, Eurobioplex EBX071 and Altostar

M.P. Anolli, S. Uceda Renteria, E. Degasperri, F. Facchetti, D. Sambarino, M. Borghi, R. Perbellini, R. Soffredini, S. Monico, A. Callegaro, P. Lampertico
Milan

75. An easy and reproducible strategy to improve the structural integrity of the albumin molecule in commercial vials


M. Baldassarre, M. Naldi, G. Zaccherini,

E. Pompili, G. Iannone, D. Tedesco, M. Nugnes, E. Fabini, K. Pock, G. Tedesco, O. Hegener, M. Bartolini, P. Caraceni
Bologna, Vienna (Austria)

76. Outcome of hepatic resection for hepatocellular carcinoma in ideal and non-ideal candidates

L. Lani, L. Bucci, V. Santi, B. Stefanini, B. Stefanini, A. Sangiovanni, S. Grasselli, G. Ghittoni, C. Saitta, F. Morisco, G. Cabibbo, F. Marra, G. Vidili, M.R. Brunetto, F.G. Foschi, M. Di Marco, G. Svegliati Baroni, F. Pelizzaro, F. Azzaroli, F.R. Ponziani¹⁸, A. Martini, D. Sacerdoti, A. Mega, S. Boninsegna, E.G. Giannini, D. Magalotti, R. Sacco, G. Nardone, A. Vitale, F. Trevisani for the Italian Liver Cancer (ITA.LI.CA) group
Bologna, Milan, Parma, Viterbo, Messina, Naples, Palermo, Florence, Sassari, Pisa, Faenza (RA), Bergamo, Ancona, Padua, Rome, Verona, Bolzano, Negrar (VR), Genoa, Foggia, Naples

77. The svr10k study: a real-world data with



pangenotypic direct-acting antivirals across multiple diverse regions

G. Lai-Hung Wong, M.R. Alvares-da-Silva, F. Higuera-de-la-Tijera, M. Lung Yu, S. Aleman, J. Garcia-Samaniego, J. Cabezas, M. Casado, M. Alzaabi, A. Chandak, M. Martínez, A. Khachatryan, L. Chen, C. Hernandez, Y. Jun Wong
Hong Kong, Porto Alegre (Brazil), Ciudad de Mexico (Mexico), Kaohsiung (Taiwan), Stockholm (Sweden), La Paz (Spain), Valdecilla (Spain), Torrecárdenas (Spain), Abu Dhabi (UAE), Radnor (USA), Foster City (USA), Singapore

78. Systolic and diastolic dysfunction, but not cardiac hyper-contractility, are unrelated to liver disease severity: a multicentric cohort study

M. Bevilacqua, F. Cattazzo, S. Romano, A. Dalbeni, R. Stupia, L. De Marco, D. Ieluzzi, V. Paon, A. Comuzzi, A. Marca, R. Villani, R. Lombardi, A. Salzano, D. Sacerdoti
Verona, Foggia, Milan, Naples

79. Carriage of rare pathogenic apob variants


predispose to severe MASLD and HCC

M. Mureddu, S. Pelusi, O. Jamialahmadi, G. Periti, L. Ronzoni, H. Heigadeh, F. Malvestiti, M. Saracino, V. Moretti, V. La Mura, R. D'Ambrosio, S. Petta, AL. Fracanzani, L. Miele, U. Vespasiani Gentilucci, E. Bugianesi, D. Prati, C.V. Schneider, S. Romeo, L.V.C. Valenti
Milan, Gothenburg (Sweden), Pavia, Palermo, Rome, Turin, Aachen (Germany), Catanzaro, Stockholm (Sweden)

80. Outcomes of patients with alcohol-related cirrhosis referred to a hepatology outpatient clinic

G. Iannone, D. Pratelli, E. Pompili, C. Di Stefano, M. M. Bossi, M. Manno, M. Baldassarre, V. Guarneri, G. Tedesco, S. Lorenzini, P. Caraceni, G. Zaccherini
Bologna

81. Use of proton pump inhibitors among German Hepatitis C patients treated with sofosbuvir/velpatasvir: data from the German



hepatitis C-Registry (2016–2022)

M. Cornberg, G. Teuber, R. Link, U. Naumann, H. Klinker, C. John, C. Hernandez, M. Schwenken, C. Sarrazin

Hannover (Germany), Frankfurt am Main (Germany), Offenburg (Germany), Berlin (Germany), Würzburg (Germany), Berlin (Germany), Uxbridge (UK), Madrid (Spain), Munich (Germany), Wiesbaden (Germany)

82. Atezolizumab plus Bevacizumab does not cause subclinical cardiotoxicity evaluated by Left-Ventricular Global Longitudinal Strain

M. Bevilacqua, R. Calzamatta, R. Stupia, S. Romano, F. Cattazzo, A. Dalbeni, L. De Marco, D. Ieluzzi, V. Paon, D. Sacerdoti
Verona

83. Liver and spleen stiffness measure by transient elastography: a promising tool for the clinical management of patients after Fontan-type surgery circulation

B. Coco, L. Ait Ali, G. Petralli, L. De Stefano, P. Colombatto, R. Vukotic, A. Salvati, F. Bonino,

P. Festa, M.R. Brunetto
Pisa, Massa, Naples


84. Use of Glucagon-like Peptide-1 Receptor Agonist is associated with reduced risk of major liver-related events: a meta-analysis

C. Celsa, G. Pennisi, A. Tulone, G. Ciancimino, M. Vaccaro, G. Di Maria, G. Infantino, M. Enea, C. Cammà, S. Petta
Palermo

85. Skin injuries prevention during TIPS creation: use of “alert levels” and “trigger levels” in a high volume TIPS referral hospital (20 procedures/year)

C.M. Giacchetto, B. Magro, L. Marruzzelli, A. Galante, R. Miraglia
Palermo

86. The relationship between serum bile acids and event-free survival following the use of maralixibat for progressive familial intrahepatic cholestasis: data from MARCH/MARCH-ON



L. D'Antiga, R.J. Thompson, S.P. Horslen, D.B. Mogul, T. Nunes, W. Garner, P. Vig, A.G. Miethke

Bergamo, London (UK), Pittsburgh (USA), Foster City (USA), Cincinnati (USA)

87. Characterization of transcriptional and functional CD8 T cell heterogeneity to design individualized correction strategies for chronic HBV infection

M. Rossi, A. Vecchi, F. Guerrieri, C. Tiezzi, M.L. Plissonnier, E. Degasperi, D. Sambarino, P. Fisicaro, E.A. Gabor, S. Doselli, B. Farina, G. Missale, P. Lampertico, C. Ferrari, M. Levrero, C. Boni

Parma, Lyon (France), Milan, Rome

88. Assessing perilipin-2 as a liver-specific biomarker: lack of correlation between cardiac damage and its levels in heart failure patients

L. Petrucci, G. Angelini, I. Fumarulo, S. Russo, A. Liguori, M. Vaccarella, B. Garramone, M. Massetti, A. Gasbarrini, G. Mingrone,

N. Aspromonte, L. Miele
Rome


89. Clinical benefits of maralixibat for patients with Alagille syndrome are durable through 7 years of treatment: data from the MERGE study

D.A. Kelly, B.M. Kamath, E. Gonzales, K.F. Murray, D.H. Leung, D.B. Mogul, A. Sogliani, W. Garner, P. Vig, E. Jacquemin
Birmingham (UK), Philadelphia (USA), Toronto (Canada), Paris (France), Cleveland (USA), Houston (USA), Foster City (USA)

90. Gaps in metabolic dysfunction-associated steatotic liver disease (MASLD) screening and management: a retrospective audit of patients at cardiometabolic risk in secondary care

M. Cucco, R. De Maria, C. Pavanello, L. Cesarini, G. Mombelli, A. Alberti, F. Bertuzzi, L. S. Belli, L. Calabresi
Milan

91. Liver disease is highly prevalent in patients



with hereditary transthyretin-related amyloidosis

C. Pitrone, R. Filomia, M.S. Franzè, M. Barresi, G. Caccamo, P. Liotta, L. Teresi, M. De Luca, M. Russo, A. Mazzeo, I. Cacciola, G. Di Bella, C. Saitta
Messina

92. Relationship between recipient/donor features and liver stiffness measurement in the first year after liver transplantation

C. Dibenedetto, E. Sguazzini, M. Sagasta, L. Caccamo, B. Antonelli, M.F. Donato, P. Lampertico
Milan

93. Bone fragility and fracture risk assessment in metabolic dysfunction-associated steatotic liver disease

C. Asero, C. Oliveri, M.S. Franzé, A. Di Giovanni, R. Filomia, G. Caccamo, C. Pitrone, C. Saitta, C. Morace, N. Morabito, G. Basile, A. Catalano, I. Cacciola

Messina

94. Direct effects of psilocybin on serotonin receptors regulate lipid accumulation in hepatic cells and adipocytes


A. Signor, M. Colognesi, D. Gabbia, I. Zanotto, Y. Frion-Herrera, S. Comai, A. Mattarei, G. Pasut, F. Folli, M. Pappagallo, P. Manfredi, S. De Martin
Padua, Milan, Coral Gables (USA)

95. Beneficial effect of the combination psilocybin-semaglutide in a murine model of Steatotic Liver Disease

M. Colognesi, D. Gabbia, A. Signor, S. Comai, A. Mattarei, G. Pasut, F. Folli, L. Centofanti, S. La Rosa, G. Finzi, M. Pappagallo, P. Manfredi, S. De Martin
Padua, Milan, Varese, Coral Gables (USA)

96. Outcome and predictors of major adverse cardiovascular events after liver transplantation: a single center experience

E.V. Pesatori, L. Pasulo, M. Viganò, F. Leonardi,



A. Rossi, S. Camagni, F. Neri, A. Loglio, D. Pinelli,
S. Fagioli
Bergamo, Milan

97. Improving effects of sacubitril/valsartan on hepatic fibrosis in MASLD patients with heart failure

G. Fabris, L. Portolan, M. Zoncapè, L.A. Natola,
D. Sacerdoti, A. Piccoli, A. Dalbeni
Verona

98. A multicenter analysis on efficacy and safety of Tenofovir alafenamide (TAF) in a wide cohort of patients with chronic hepatitis B (CHB)

M. Tizzani, G.P. Caviglia, A. Frasson, E. Degasperis,
M. Viganò, M. Borghi, D. Sambarino, A. Loglio,
E. Farina, S. Fagioli, P. Lampertico, A. Marzano
Turin, Milan, Bergamo

99. Prognostic value of liver stiffness trends vs. absolute values after sustained virological response in HCV-related advanced chronic liver disease. A monocentric retrospective study

F. Cerini, J. Schropp, A. Cosenza, C. Selvaggio,
C. Masellis, M. Rumi, A. Berzigotti
Milan, Bern (Switzerland)


100. Epidemiologic features influencing the selection of direct acting antivirals (DAA) in HCV patients: an Italian real-world study

N. Pugliese, F. Conti, V. Rosato, P. Gallo, S. Gitto,
F. Frigerio, V. Perrone, C. Veronesi, M. Cappuccilli,
L. Degli Esposti, M. Riglietta, A. Mangia
Rozzano (MI), Faenza (RA), Naples, Rome,
Florence, Milan, Bologna, Bergamo, S. Giovanni
Rotondo (FG)

101. Pathogenic pathways in MASLD: comparison between "Metabolic" and "Genetic" MASLD, a multiOmics cohort study

P. Torre, B.M. Motta, M. Lombardi, T. Sarcina,
R. Coppola, M. Festa, J. Troisi, M. Masarone,
M. Persico
Baronissi (SA), Montecorvino Pugliano (SA)

102. Outcomes of HBV and HCV testing in



Italy's marginalized communities: a step towards WHO plan to end viral hepatitis as a public health threat by 2030

I. De Giorgi, M. Monti, T. Caruso, A. Castellaccio, G. Cavallini, M.L. Manca, S. Lorini, S. Marri, L. Petraccia, F. Madia, C. Stasi, L. Carraresi, E. Lorefice, S.I. Bonelli, A. Nerli, L. Martini, S. Gitto, D. Aquilini, P. Blanc, A.L. Zignego, L. Gragnani

Florence, Pisa, Pistoia, Rome, Siena, Empoli (FI), Prato

103. Exploring the interplay between sarcopenia, liver and cardiovascular damage in non-cirrhotic MASLD patients: a genetic perspective

F. Alletto, A. Cespiati, R. Lombardi, F. Santomena, G. Pisano, G. Oberti, C. Bertelli, R. Forlano, P. Manousou, P. Dongiovanni, A.L. Fracanzani
Milan, London (UK)

104. Prognostic implications of minimal serum

creatinine fluctuations in acutely decompensated cirrhosis


M. Botta, M. Tizzani, A. Calleri, C. Lisi, G. Pecorella, M. L. Robone, M. Bonomo, E. Bertoldi, F. Frigo, D. Campion, A. Ottobrelli, A. Marzano, E. Bugianesi, G. M. Saracco, C. Alessandria
Turin

105. Baseline liver elastography and its longitudinal changes predict liver related outcomes in patients with Metabolic dysfunction Associated Steatotic Liver Disease (MASLD)

A. Liguori, L. Petrucci, F. Pantaleo, F.S.M. Youssef, G. Marrone, M. Biolato, M. Pompili, A. Grieco, A. Gasbarrini, L. Miele
Rome

106. Coagulation imbalance is associated with hepatic and vascular complications in patients with MASLD and diabetes: key role of factor VIII

R. Lombardi



Milan, London (UK), Tricase (LE)

107. MiR-22-3p targets the G2/M checkpoint inhibitor Wee1 and represents a possible biomarker of TACE response in hepatocellular carcinoma

G. Galvani, C. Vianello, I. Leoni, E. Monti, G. Marisi, A. Casadei Gardini, G.F. Foschi, M.L. Lazzari, C. Giovannini, G. Ravegnini, I. Salamon, M. Ferracin, F. Piscaglia, M. Negrini, C. Stefanelli, D. Trerè, L. Gramantieri, F. Fornari
Rimini, Meldola (FC), Milan, Faenza (RA), Bologna, Ferrara

108. Prevalence and influence of diabetes mellitus on clinical outcomes in patients hospitalized for acutely decompensated cirrhosis

M. Bonomo, A. Calleri, M. Tizzani, C. Lisi, G. Pecorella, M. L. Robone, M. Botta, F. Frigo, D. Campion, A. Ottobrelli, A. Marzano, E. Bugianesi, G.M. Saracco, C. Alessandria
Turin

109. Checkpoint inhibitor-induced liver injury (ChILI) in patients with advanced skin cancer: a single center experience


A. Liguori, S. Archilei, M. Salvi, G. Marrone, M. Biolato, L. Miele, M. Pompili, A. Di Stefani, K. Peris, A. Gasbarrini, A. Grieco
Rome

110. Rectus femoris cross sectional area predicts 90-day readmission in patients hospitalized for an acute decompensation of cirrhosis

R. Gagliardi, P. Campadello, S. Brocco, S. Incicco, V. Calvino, B. Sikadi, M. Tonon, A. Brocca, C.G. Gambino, N. Zeni, G. De Conti, C. Giraudo, P. Angeli, S. Piano
Padua

111. Determinants of liver stiffness measurements changes in Metabolic dysfunction-Associated Steatotic Liver Disease: insights from two cohorts

M. Zoncapè, A. Liguori, S. Pelusi, C. Bianco,



*D. Roccarina, L. Iogna Prat, A. Mantovani,
J. Clancy, A. Goyale, L. Valenti, E.A. Tsochatzis
London (UK), Verona, Rome, Milan*

**112. Liver stiffness measurement by SuperSonic
Imagine two-dimensional shear wave
elastography to predict hepatocellular
carcinoma in non-cirrhotic metabolic
dysfunction-associated steatotic liver disease**

*M.G. Indre, B. Stefanini, C. Abbati, M. Boe,
R. Cappelli, R. Chen, E. Santangeli, F. Tovoli,
M.C. Morelli, F. Piscaglia, S. Ferri, F. Ravaioli
Bologna*

**113. A peculiar composition of HBsAg isoforms
characterizes chronic HDV coinfection respect
to HBV mono-infection with higher middle -
and large - HBs levels reflecting a more intense
HDV activity**

*A. Magnapera, L. Piermatteo, S. D'Anna, A. Olivero,
L. Duca, G. Torre, C. Castelli, E. Teti, A. Di Lorenzo,
V. Malagnino, M. Iannetta, L. Baiocchi, S. Francioso,
I. Lenci, F. Ceccherini-Silberstein, M. Milella,*


*A. Saracino, A. Ciancio, L. Sarmati, P. Lampertico,
M. Rizzetto, G.P. Caviglia, V. Svicher, R. Salpini
Rome, Turin, Bari, Milan*

**114. Evaluation of the intratumoral immune
microenvironment in hepatocellular carcinoma
treated with liver surgery after selective internal
radiation therapy**

*M.S. Franzè, H. Dahboul, A. Beaufrère,
M. Bouattour, M. Lesurtel, M. Ronot, V. Paradis,
A. Luciani, H. Kobeiter, D. Sommacale, V. Leroy,
R. Brustia, H. Regnault, J. Calderaro, G. Amaddeo
Créteil (France), Messina, Clichy (France)*

**115. Cardiopulmonary hemodynamics and liver
stiffness changes in predicting cardiac
decompensation after TIPS: a prospective study**

*D. Saltini, T. Guasconi, C. Caporali, M. Bianchini,
F. Casari, F. Prampolini, B. Lei, M. Scoppettuolo,
F. Ascari, A.S. Velasco Mayorga, A. Piscopo,
A. Colecchia, F. Schepis
Modena*



116. The impact of first and further decompensation in patients with metabolic-dysfunction associated compensated advanced chronic liver disease

G. Pennisi, G. Di Maria, V.W.S. Wong, V. de Ledingham, G. Sebastiani, M. Viganò, A.L. Fracanzani, L. Miele, E. Bugianesi, M. Ekstedt, R. D'Ambrosio, F. Ravaioli, F. Schepis, F. Marra, A.M. Aghemo, G. Svegliati Baroni, M. Persico, L. Valenti, A. Berzigotti, J. George, A. Armandi, P. Nasr, S. Kechagias, D. Saltini, Y.P. Mendoza, V. Calvaruso, M. Enea, H. Lin, G. Infantino, M. Masarone, N. Pugliese, A. Tulone, V. Di Marco, C. Cammà, S. Petta
Palermo, Hong Kong, Pessac (France), Montreal (Canada), Milan, Rome, Turin, Linköping (Sweden), Bologna, Modena, Florence, Rozzano (MI), Ancona, Salerno, Bern (Switzerland), Sydney (Australia)

117. Our Hub Hospital experience with adult liver transplantation referral in hepatic cirrhosis

E. Garlatti Costa, E. Fornasiere, S. Fumagalli,


E. Fumolo, A. Ferrarese, G. Dettori, S. Venturini, D. Bitetto, G. Germani, P. Toniutto, P. Burra, S. Grazioli
Pordenone, Udine, Padua

118. Prevalence and clinical impact of rectal colonization by multidrug-resistant (MDR) bacteria in patients with acute decompensation of cirrhosis

N. Zeni, J. Bañares, M. La Franca, S. Incicco, R. Gagliardi, A. Barone, A. Accetta, V. Calvino, G. Antonacci, A. Romano, C. Gambino, M. Tonon, P. Angeli, S. Piano
Padua, Barcelona (Spain)

119. More advanced presentation but similar survival for hepatocellular carcinoma in HIV positive compared to HIV-negative patients: a retrospective cohort analysis

M. Iavarone, E. Alimenti, M. Puoti, H. Hasson, B. Monti, F. Peracchi, A. Siribelli, M. Fava, M. Bruccoleri, M. Merli, G. Morsica, A. De Silvestri, P. Bonfanti, A. Castagna,



A. Soria, P. Lampertico
Milan, Monza, Pavia

120. Clinical characterization and evolution of disease in a large cohort of 196 patient with autoimmune hepatitis in a referral center

S. Vavassori, F. Samartin, C. Limosani, L. Pastorelli,
A.L. Crosignani, E. Bertolini, P.M. Battezzati
Milan


121. Assessment of response and impact of safety treatment with bulevirtide in patients with chronic delta virus infection: an observational trial for evaluating long-term efficacy. the ARISTOTELE pilot study

L. Rinaldi, M. Viganò, V. Messina, A. Caturano,
G. Niro, N. Capoluongo, A. Loglio, L. Marinaro,
A. Marrone, E. Claar, M. Russello, E. Ciraci,
U. Vespasiani Gentilucci, A. Ciancio, V. Pace Palitti,
C. Acierno, A. Mormone, R. Cotugno,
F. Terracciani, P. Gallo, M.R. Cannavò, V. Rosato,
F. Benanti, P. Cariti, E. Falbo, M. di Stefano,
R. Sacco, A. Perrella, A. Izzi

Campobasso, Bergamo, Caserta, Naples, San
Giovanni Rotondo (FG), Turin, Catania, Ostuni
(BR), Rome, Pescara, Potenza, Catania, Lamezia
Terme (CZ), Siracusa, Foggia

122. Outcomes of durvalumab with or without tremelimumab in routine clinical practice according to HIMALAYA Trial Eligibility: preliminary results of the international DT-real study

C. Celsa, N. Nishida, S.M. Chamseddine,
A. Arvind, M. Li, H. Toyoda, S. Ulahannan,
C.A.M. Fulgenzi, G.F. Manfredi, A. D'Alessio,
B. Stefanini, G. Cabibbo, C. Cammà, B. Scheiner,
L. Rimassa, R.K. Kelley, A.G. Singal, A.O. Kaseb,
M. Kudo, D.J. Pinato
London (UK), Palermo, Osaka (Japan), Houston
(USA), Dallas (USA), San Francisco (USA), Gifu
(Japan), Oklahoma City (USA), Novara, Bologna,
Vienna (Austria), Pieve Emanuele (MI), Rozzano
(MI)



123. Multiparametric ultrasound for the prediction of the outcomes of endoscopic variceal band ligation

R. Borriello, V. Calvez, G. Esposto, I. Mignini, M.E. Ainora, L. Galasso, A. Gasbarrini, M.A. Zocco
Rome

124. The prognostic role of LiverRisk score in patients with compensated cirrhosis

M. Tonon, A. Accetta, S. Incicco, R. Gagliardi, N. Zeni, V. Santori, V. Calvino, G. Antonacci, C.G. Gambino, S. Piano
Padua

125. Survey on acute on chronic liver failure in internal medicine departments and transplant centers of Lazio


M. Delle Monache, M. Carli, C. Conigliani, F. Pascucci, G.M. Ettorre, N. Guglielmo, L. Baiocchi, I. Lenci, Q. Lai, V. Ramundo, C. Ripani, S. Furfaro, A. Cappelli and Area Epatologica FADOI Lazio
Rome

126. The changing scenario in hepatocellular carcinoma management: the Niguarda experience

C. Mazzearelli, R. Viganò, G. Perricone, L. Cesarini, A. Airoidi, M. Vangeli, M. Carbone, C. Becchetti, M. Cucco, R. Stigliano, F. Aprile, G. Dispenzeri, A. Lauterio, I. Mangoni, V. Buscemi, F. Ferla, A. Mariani, G. Checchini, R. De Carlis, L. Centonze, R. Cerchione, F. Morelli, A. Alfonsi, P. Brambillasca, F. Villa, K. Bencardino, A. Vanzulli, C. Sgrazutti, I. Vicentin, M. Palazzi, D. Sibio, C. Rossetti, G. Cabrini, S. Capitanio, M. Solcia, L.G. De Carlis, L.S. Belli
Milan

127. Safety considerations for finite nucleos(t)ide analogue (NA) in Chronic Hepatitis B infection, a single-center, observational and retrospective study

M. Calia, E. Asperges, V. Zuccaro, L. Maiocchi, S. Paolo, R. Bruno
Pavia



128. Non invasive tests to rule out clinical significant portal hypertension and high- risk varices in autoimmune hepatitis

A. Gerussi, A. Bonfichi, L. Capodicasa, G. Di Maria, L. Cristoferi, F. Malinverno, M.C. Neglia, C. Celsa, M. Carbone, A. Di Sabatino, P. Invernizzi, V. Calvaruso
Monza, Pavia, Palermo, Milan

129. Longitudinal analysis of viral profiles in chronic HBV/HDV coinfectd patients

C. Musolino, V. Chines, D. Lombardo, D. Giosa, S. Franzè, G. Raffa, D. Ferraro, I. Cacciola, V. Di Marco, G. Raimondo, T. Pollicino
Messina, Palermo

130. Etiology-specific Coronary Artery Calcium Score thresholds for cardiovascular risk stratification in liver transplant candidates


N. Sperduti, C. Telesca, S. Demma, D. Cartoni, A. Pingitore, V. Buffa, A. Pellicelli, G.M. Ettore, V. Giannelli
Rome

131. Alkaline Phosphatase Changes With Seladelpar Across Subgroups Of Primary Biliary Cholangitis Patients In The Response Trial

K. Kowdley, K. Yimam, S. Kumar, E. Mena, A. Bonder, K. Gautham Reddy, C. Corpechot, S. Carroll, F. Frigerio, K. Yang, D.B. Crittenden, C. McWherter
Seattle (USA), San Francisco (USA), New York (USA), Pasadena (USA), Boston (USA), Chicago (USA), Paris (France), Foster City (USA), Fremont (USA)

132. Long-Term Efficacy and Safety of Open-Label Seladelpar Treatment in Patients With Primary Biliary Cholangitis: Pooled Interim Results for up to 3 Years From the ASSURE Study

E.J. Lawitz, P.J. Trivedi, K. V. Kowdley, S.C. Gordon, C.L. Bowlus, M.C. Londoño, G.M. Hirschfield, A. Gulamhusein, D.B. Crittenden, F. Frigerio, S. Zhuo, C. Heusner, C. Levy
San Antonio (USA), Birmingham (UK), Seattle (USA), Detroit (USA), Sacramento (USA),



Barcelona (Spain), Toronto (Canada), Foster City (USA), Fremont (USA), Miami (USA)

133. At the boundaries: analyzing short and long-term outcome after paediatric liver transplantation: Padua experience

A. Ferrarese, M. Cananzi, L. Bosa, A. Dolcet, M. Senzolo, F.P. Russo, G. Germani, M. Gambato, A. Zanetto, E. Catanzaro, M. Grasso, F. D'Arcangelo, M.L. Vivian, E. Gringeri, U. Cillo, P. Burra
Padua

134. A proof of concept study evaluating the role of lipopolysaccharide-induced tumor necrosis factor in hepatocellular carcinoma

R. Piciotti, F. Tiano, N. Panera, M. Bianchi, N. Cicolani, A. Alisi
Rome

135. The devastating impact of severe pruritus in primary biliary cholangitis


H.T. Smith, M.M. McLaughlin, S. Das, A. Ribeiro,

P. Andreone, P. J.F. Trok, A. E Kremer, D. Jones
London (UK), Collegeville (USA), Hyderabad (India), Madrid (Spain), Baggiovara (MO), Zürich (Switzerland), Newcastle (UK)

136. Domino liver transplantation from an adult patient with propionic acidemia: a case report of the first documented case worldwide

M. Stecchi, F. Mirici Cappa, V. Vero, R. Di Donato, A. Baldan, M.C. Morelli, M. Cescon, P. Pianta, L. Brodosi
Bologna





FACULTY

Ludovico Abenavoli *Catanzaro*

Alessio Aghemo *Milano*

Paolo Angeli *Padova*

Sherrie Bhoori *Milano*

Giuseppina Brancaccio *Padova*

Rossana Brunetto *Torino*

Raffaele Bruno *Pavia*

Elisabetta Bugianesi *Torino*

Patrizia Burra *Padova*

Giuseppe Cabibbo *Palermo*

Paolo Caraceni *Bologna*

Marco Carbone *Milano*

Nora Cazzagon *Padova*

Umberto Cillo *Padova*

Ernesto Claar *Napoli*

Antonio Craxì *Palermo*

Laura Cristoferi *Monza*

Lorenzo D'Antiga *Milano*

Elisabetta Degasperì *Milano*


Nicoletta De Matthaeis *Roma*

Vito Di Marco *Palermo*

Marco Di Nicola *Roma*

Daniele Eliseo Dondossola *Milano*

Stefano Fagiuoli *Bergamo*



FACULTY

Alessandro Federico *Napoli*

Anna Ludovica Fracanzani *Milano*

Mirella Fraquelli *Milano*

Giovanni Galati *Roma*

Ivan Gardini *Monza*

Antonio Gasbarrini *Roma*

Valerio Giannelli *Roma*

Edoardo Giannini *Genova*

Antonio Grieco *Roma*

Massimo Iavarone *Milano*

Pietro Invernizzi *Milano*

Pietro Lampertico *Milano*

Fabio Marra *Firenze*

Silvia Martini *Torino*

Marco Marzioni *Roma*

Mario Masarone *Salerno*

Luca Miele *Roma*

Sara Montagnese *Padova*

Maria Cristina Morelli *Bologna*


Filomena Morisco *Napoli*

Duilio Pagano *Palermo*

Giovanni Perricone *Milano*

Marcello Persico *Salerno*

Salvatore Petta *Palermo*



Salvatore Silvio Piano *Padova*

Fabio Piscaglia *Bologna*

Teresa Pollicino *Messina*

Francesca Ponziani *Roma*

Thomas Reiberger *Vienna, Austria*

Maria Rendina *Bari*

Cristina Rigamonti *Novara*

Davide Roccarina *Firenze*

Vincenzo Ronca *Pieve Emanuele, MI*

Francesco Paolo Russo *Padova*

Rodolfo Sacco *Foggia*

Carlo Saitta *Messina*

Federico Salomone *Catania*

Filippo Schepis *Modena*

Marco Senzolo *Padova*

Gianluca Svegliati Baroni *Ancona*

Pierluigi Toniutto *Udine*

Giulia Tosetti *Milano*


Luca Valenti *Milano*

Umberto Vespasiani Gentilucci *Roma*

Mauro Viganò *Milano*

Alessandro Vitale *Padova*

Giacomo Zaccherini *Bologna*



SEDE DEL MEETING

Centro Congressi Auditorium della Tecnica

Viale Umberto Tupini, 65 • 00144 Roma

ISCRIZIONE

Soci AISF

Per i Soci AISF in regola con il versamento delle quote associative la partecipazione è gratuita.

Sarà indispensabile regolarizzare la propria posizione associativa entrando nell'Area Soci del sito web AISF col proprio profilo utente.

PAGAMENTO QUOTA AISF >

Per iscriversi all'evento cliccare qui:

ARISTEA PASS >

Nuovi Soci AISF

Per accedere in qualità di Socio AISF all'Evento Formativo è necessario iscriversi all'Associazione cliccando qui:

ISCRIZIONE ALL'AISF >

L'iscrizione all'AISFdà diritto alla partecipazione gratuita alle Riunioni Istituzionali "Riunione Generale Annuale", "Riunione Monotematica" e "Special Conference", all'abbonamento gratuito alla rivista Digestive and Liver Disease ed a ricevere qualsiasi informazione relativa all'attività dell'Associazione.

Non Soci AISF

€ 300,00 (inclusa IVA 22%)

Le quote di iscrizione includono: l'accesso alle Sessioni Scientifiche, coffee breaks, lunches, l'attestato di partecipazione, l'attestato E.C.M. (se conseguito).

Per iscriversi all'evento clicca qui:

ARISTEA PASS >

Termine per Iscrizione all'Annual Meeting:
28 Febbraio 2025

Al termine dell'iscrizione, riceverete un e-badge via e-mail. Vi preghiamo di conservarlo sul vostro smartphone e, in sede di evento, scansionare il QR code presente sull'e-badge ai terminali self-service nella zona di benvenuto e stampare quindi il badge di accesso ai lavori congressuali. Il Pre Meeting e l'Annual Meeting



prevedono due distinti e-badge di registrazione.

Cancellazione e rimborsi

Le cancellazioni pervenute entro il giorno 28 Febbraio 2025, tramite comunicazione scritta alla Segreteria Organizzativa, daranno diritto ad un rimborso totale dell'importo versato, detratto l'importo di € 15,00 per spese amministrative.

Superata tale data non saranno riconosciuti rimborsi. I rimborsi saranno effettuati solo dopo il termine dell'Evento.

E.C.M. - EDUCAZIONE CONTINUA IN MEDICINA E DESTINATARI ATTIVITÀ FORMATIVA

Il Congresso è stato inserito dall'AISF – Provider accreditato dalla Commissione Nazionale per Formazione Continua con il numero di accreditamento 1547-439416 – nel proprio piano formativo 2025 nell'ambito del Programma Nazionale E.C.M. (Educazione Continua in Medicina). L'Evento Formativo è stato accreditato **per n. 500 partecipanti**, per la categoria professionale Medico Chirurgo, specializzata per le seguenti discipline: Gastroenterologia, Malattie Infettive, Medicina Interna, Chirurgia Generale, Microbiologia e Virologia, Anatomia


Patologica, Medicina Generale - Medici di Famiglia e riconosce n. 2,4 crediti. I crediti saranno rilasciati esclusivamente ai partecipanti appartenenti alle professioni ed alle discipline indicate che rientreranno nel numero massimo di partecipanti per il quale l'evento è stato accreditato.

OBIETTIVO FORMATIVO

Applicazione nella pratica quotidiana dei principi e delle procedure dell'evidencebased practice (EBM - EBN - EBP)

VALUTAZIONE E CERTIFICAZIONE DEI CREDITI E.C.M.

L'attestazione dei crediti è subordinata alla partecipazione effettiva all'intero evento formativo, nella misura del 100%, ed alla compilazione dell'Autodichiarazione obbligatoria e della Scheda di Valutazione evento. L'attestato, riportante il numero di crediti assegnati, verrà pertanto rilasciato dopo avere effettuato tali verifiche e sarà quindi disponibile online – entro 60 giorni dopo la chiusura dell'evento – sul sito web www.aris-teaeducation.it



INFORMAZIONI

L'accesso alla documentazione sarà attivato al termine di ogni Sessione E.C.M. per le successive 72 ore. Il mancato rispetto dei suindicati requisiti non darà diritto ai crediti E.C.M., ma solamente all'attestato di partecipazione.

ATTESTATO DI PARTECIPAZIONE

L'attestato di partecipazione sarà disponibile per il download sulla piattaforma internet:
<https://online.aristea.com/login>

PROVIDER E.C.M. (ID 1547)



AISF - Associazione Italiana per lo Studio del Fegato

Viale Maresciallo Pilsudski, 118 • 00197 Roma
Tel. 06 86399303 • E-mail info@webaisf.org
Web www.webaisf.org

SEGRETERIA ORGANIZZATIVA



Viale Maresciallo Pilsudski, 118 • 00197 Roma
Tel. 06 845431 • E-mail roma@aristea.com
Web www.aristea.com



<https://aisfnazionale2025.it>

